<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">73407</article-id><article-id pub-id-type="doi">10.7554/eLife.73407</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title><italic>ahctf1</italic> and <italic>kras</italic> mutations combine to amplify oncogenic stress and restrict liver overgrowth in a zebrafish model of hepatocellular carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-252790"><name><surname>Morgan</surname><given-names>Kimberly J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7871-2583</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-139585"><name><surname>Doggett</surname><given-names>Karen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8676-8461</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-301788"><name><surname>Geng</surname><given-names>Fansuo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-299544"><name><surname>Mieruszynski</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-68330"><name><surname>Whitehead</surname><given-names>Lachlan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-250606"><name><surname>Smith</surname><given-names>Kelly A</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-63164"><name><surname>Hogan</surname><given-names>Benjamin M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0651-7065</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253677"><name><surname>Simons</surname><given-names>Cas</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253678"><name><surname>Baillie</surname><given-names>Gregory J</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-253679"><name><surname>Molania</surname><given-names>Ramyar</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-24358"><name><surname>Papenfuss</surname><given-names>Anthony T</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-103396"><name><surname>Hall</surname><given-names>Thomas E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7718-7614</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-59761"><name><surname>Ober</surname><given-names>Elke A</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-7189"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0382-0026</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-235881"><name><surname>Gong</surname><given-names>Zhiyuan</given-names></name><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-142183"><name><surname>Heath</surname><given-names>Joan K</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6955-232X</contrib-id><email>joan.heath@wehi.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01b6kha49</institution-id><institution>Epigenetics and Development Division, Walter and Eliza Hall Institute of Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>Department of Medical Biology, University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01b6kha49</institution-id><institution>Centre for Dynamic Imaging, Advanced Technology and Biology Division, Walter and Eliza Hall Institute of Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01ej9dk98</institution-id><institution>Department of Physiology, University of Melbourne</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rqy9422</institution-id><institution>Institute for Molecular Biosciences, University of Queensland</institution></institution-wrap><addr-line><named-content content-type="city">Queensland</named-content></addr-line><country>Australia</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02a8bt934</institution-id><institution>Peter MacCallum Cancer Centre</institution></institution-wrap><addr-line><named-content content-type="city">Melbourne</named-content></addr-line><country>Australia</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/048fyec77</institution-id><institution>Murdoch Children's Research Institute</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01b6kha49</institution-id><institution>Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research</institution></institution-wrap><addr-line><named-content content-type="city">Parkville</named-content></addr-line><country>Australia</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/035b05819</institution-id><institution>Danish Stem Cell Center, University of Copenhagen</institution></institution-wrap><addr-line><named-content content-type="city">Copenhagen</named-content></addr-line><country>Denmark</country></aff><aff id="aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Department of Developmental Genetics, Max Planck Institute for Heart and Lung Research</institution></institution-wrap><addr-line><named-content content-type="city">Bad Nauheim</named-content></addr-line><country>Germany</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tgyzw49</institution-id><institution>Department of Biological Science, National University of Singapore</institution></institution-wrap><addr-line><named-content content-type="city">Singapore</named-content></addr-line><country>Singapore</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>White</surname><given-names>Richard M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e73407</elocation-id><history><date date-type="received" iso-8601-date="2021-08-27"><day>27</day><month>08</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2023-01-16"><day>16</day><month>01</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2021-08-27"><day>27</day><month>08</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.08.25.457580"/></event></pub-history><permissions><copyright-statement>© 2023, Morgan et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Morgan et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-73407-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-73407-figures-v2.pdf"/><abstract><p>The nucleoporin (NUP) ELYS, encoded by <italic>AHCTF1</italic>, is a large multifunctional protein with essential roles in nuclear pore assembly and mitosis. Using both larval and adult zebrafish models of hepatocellular carcinoma (HCC), in which the expression of an inducible mutant <italic>kras</italic> transgene (<italic>kras<sup>G12V</sup></italic>) drives hepatocyte-specific hyperplasia and liver enlargement, we show that reducing <italic>ahctf1</italic> gene dosage by 50% markedly decreases liver volume, while non-hyperplastic tissues are unaffected. We demonstrate that in the context of cancer, <italic>ahctf1</italic> heterozygosity impairs nuclear pore formation, mitotic spindle assembly, and chromosome segregation, leading to DNA damage and activation of a Tp53-dependent transcriptional programme that induces cell death and cell cycle arrest. Heterozygous expression of both <italic>ahctf1</italic> and <italic>ranbp2</italic> (encoding a second nucleoporin), or treatment of heterozygous <italic>ahctf1</italic> larvae with the nucleocytoplasmic transport inhibitor, Selinexor, completely blocks <italic>kras<sup>G12V</sup></italic>-driven hepatocyte hyperplasia. Gene expression analysis of patient samples in the liver hepatocellular carcinoma (LIHC) dataset in The Cancer Genome Atlas shows that high expression of one or more of the transcripts encoding the 10 components of the NUP107–160 subcomplex, which includes <italic>AHCTF1</italic>, is positively correlated with worse overall survival. These results provide a strong and feasible rationale for the development of novel cancer therapeutics that target ELYS function and suggest potential avenues for effective combinatorial treatments.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>kras oncogene</kwd><kwd>ahctf1</kwd><kwd>Elys</kwd><kwd>nucleoporin</kwd><kwd>synthetic lethality</kwd><kwd>hepatocellular carcinoma</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>Project GNT 1024878</award-id><principal-award-recipient><name><surname>Heath</surname><given-names>Joan K</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Australian Government</institution></institution-wrap></funding-source><award-id>Graduate Student Training Program</award-id><principal-award-recipient><name><surname>Morgan</surname><given-names>Kimberly J</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>Ludwig Institute for Cancer Research</institution></institution-wrap></funding-source><award-id>Ludwig Member Support Package</award-id><principal-award-recipient><name><surname>Heath</surname><given-names>Joan K</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection, and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>ELYS, a multifunctional protein with critical roles in the cell cycle, is essential for the vigorous proliferation and survival of difficult-to-treat cancers carrying mutations in the KRAS oncogene, making it a compelling target for novel drug treatments.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Synthetic lethality describes the death of cells in response to individual mutations in two separate genes, neither of which is lethal alone. The phenomenon has emerged as a promising framework for cancer drug development (<xref ref-type="bibr" rid="bib16">Gao and Lai, 2018</xref>). Inherent to the approach is the capacity to induce the death of a vulnerable cell population, such as oncogene-expressing cancer cells, and leave healthy cells unaffected. In the clinic, the use of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors to successfully treat tumours carrying mutations in the breast cancer susceptibility genes, <italic>BRCA1</italic>/<italic>BRCA2</italic> (<xref ref-type="bibr" rid="bib31">Lord and Ashworth, 2017</xref>), has validated the approach and driven the search for other clinically relevant gene pairings, including those that confer synthetic lethality in cancer cells expressing oncogenic mutations in <italic>KRAS</italic> (<xref ref-type="bibr" rid="bib32">Luo et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Wang et al., 2017</xref>). In this paradigm, the interacting gene is neither mutated nor oncogenic in its own right. Rather, its function is essential to maintain the tumourigenic state, inspiring the concept of non-oncogene addiction (<xref ref-type="bibr" rid="bib52">Solimini et al., 2007</xref>).</p><p>In this study, we tested whether <italic>AHCTF1</italic> exhibits the properties of a synthetic lethal interacting gene with mutant <italic>KRAS</italic>. We became interested in <italic>AHCTF1</italic> when we and others showed that homozygous inheritance of an ENU-induced nonsense mutation in the zebrafish <italic>ahctf1</italic> gene (<italic>ahctf1<sup>ti262</sup></italic>) (<xref ref-type="bibr" rid="bib13">de Jong-Curtain et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Davuluri et al., 2008</xref>) disrupted nuclear pore formation and caused catastrophic levels of cell death in the intestinal epithelium and other highly proliferative cell compartments during zebrafish development (<xref ref-type="bibr" rid="bib13">de Jong-Curtain et al., 2009</xref>; <xref ref-type="bibr" rid="bib12">Davuluri et al., 2008</xref>). Meanwhile, cells in relatively quiescent tissues survived and remained healthy.</p><p><italic>AHCTF1</italic> encodes ELYS, a 252-kDa multidomain nucleoporin (NUP) that was first discovered in mice where it was shown to be required for the proliferation and survival of inner mass cells during embryonic development (<xref ref-type="bibr" rid="bib40">Okita et al., 2004</xref>). ELYS is one of 10 components of the large NUP107–160 subunit of nuclear pore complexes (NPCs). These huge (110 MDa) multi-subunit complexes comprise approximately 34 different NUPs in octameric array (<xref ref-type="bibr" rid="bib2">Beck and Hurt, 2017</xref>; <xref ref-type="bibr" rid="bib41">Petrovic et al., 2022</xref>), forming cylindrical channels in the nuclear envelope that regulate nucleocytoplasmic transport and intracellular localisation of large (&gt;40 kDa) molecules. ELYS is also indispensable for NPC reassembly after mitosis (<xref ref-type="bibr" rid="bib43">Rasala et al., 2006</xref>; <xref ref-type="bibr" rid="bib17">Gillespie et al., 2007</xref>; <xref ref-type="bibr" rid="bib14">Franz et al., 2007</xref>) and carries out a broad range of activities during the cell cycle, including chromatin decompaction, mitotic spindle assembly, and chromosome segregation (<xref ref-type="bibr" rid="bib17">Gillespie et al., 2007</xref>; <xref ref-type="bibr" rid="bib28">Kuhn et al., 2019</xref>; <xref ref-type="bibr" rid="bib18">Güttinger et al., 2009</xref>; <xref ref-type="bibr" rid="bib8">Chatel and Fahrenkrog, 2011</xref>; <xref ref-type="bibr" rid="bib34">Mishra et al., 2010</xref>; <xref ref-type="bibr" rid="bib55">Yokoyama et al., 2014</xref>; <xref ref-type="bibr" rid="bib26">Kobayashi et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Rasala et al., 2008</xref>).</p><p>Having shown previously that cells that are rapidly growing and dividing during zebrafish development are highly vulnerable to ELYS depletion, we hypothesised that cancer cells fuelled by powerful oncogenes would be vulnerable too. To test this, we took advantage of a genetically tractable zebrafish model of hepatocellular carcinoma (HCC) in which a doxycycline-inducible, hepatocyte-specific <italic>EGFP-kras<sup>G12V</sup></italic> transgene drives hepatocyte hyperplasia, liver enlargement, and morphological changes characteristic of human HCC (<xref ref-type="bibr" rid="bib10">Chew et al., 2014</xref>). We chose this model of HCC because the RAS/RAF/MAPK signalling pathway is almost always hyperactivated in human HCC (<xref ref-type="bibr" rid="bib6">Calvisi et al., 2006</xref>).</p><p>We found that reducing the expression of <italic>ahctf1</italic> mRNA by 50% disrupted multiple functions in <italic>kras<sup>G12V</sup></italic>-expressing hepatocytes and markedly impaired their growth and survival. Further studies showed that accumulation of DNA damage and robust Tp53 activation contributed to this response. These findings suggest that <italic>ahctf1</italic> and mutant <italic>kras</italic> participate in a synthetic lethal interaction that is selective for Kras oncogene-expressing cells, providing a rationale to investigate whether ELYS function could be targeted effectively and selectively by a new class of anti-cancer drugs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Molecular characterisation of mutant <italic>kras</italic>-driven zebrafish models of HCC</title><p>To generate both larval and adult models of HCC (<xref ref-type="bibr" rid="bib10">Chew et al., 2014</xref>), we varied the timing of doxycycline (dox) treatment. In our larval model, on a wildtype (WT) <italic>ahctf1</italic> background, we induced the expression of a single <italic>EGFP-kras<sup>G12V</sup></italic> transgene, denoted <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> in developing livers by treating with dox between 2 and 7 days post-fertilisation (dpf) (<xref ref-type="fig" rid="fig1">Figure 1a, b</xref>). This led to the accumulation of a constitutively active, EGFP-tagged, potently oncogenic form of Kras (Kras<sup>G12V</sup>) specifically in hepatocytes, causing hepatocyte hyperplasia and a substantial increase (4-fold) in liver volume (<xref ref-type="fig" rid="fig1">Figure 1c, d</xref>). To establish the clinical relevance of this phenotype to human HCC, we used RNA sequencing to analyse the gene expression patterns of livers expressing the <italic>kras<sup>G12V</sup></italic> transgene compared to livers expressing no transgene. We detected more than 6000 significantly upregulated genes in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers compared WT livers, and a further 6000+ genes were significantly downregulated (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1a, b</xref>). Gene set enrichment analysis identified a positive correlation between the differential gene expression data from the dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> versus WT livers and the differential gene expression data obtained from the HCC (LIHC) and healthy liver subsets available in The Cancer Genome Atlas (TCGA) (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1c</xref>). We also found a positive correlation between the diffentially expressed genes (DEGs) from the dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> versus WT livers and a small HCC expression signature based on four patient samples carrying KRAS G12 or KRAS G13 mutations (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1d</xref>). Of the upregulated genes, many were significantly enriched in KEGG pathways associated with highly proliferative cancers, including DNA replication, cell cycle regulation, and DNA damage repair (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1e</xref>). These observations build on previous reports that dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish provide an authentic model of human HCC (<xref ref-type="bibr" rid="bib57">Zheng et al., 2014b</xref>; <xref ref-type="bibr" rid="bib22">Huo et al., 2019</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title><italic>ahctf1</italic> heterozygosity restricts liver volume in a zebrafish model of <italic>kras<sup>G12V</sup></italic>-driven hepatocellular carcinoma (HCC).</title><p>(<bold>a</bold>) Protocol used to induce <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> expression in the livers of developing zebrafish larvae. (<bold>b</bold>) RT-quantitative PCR (RT-qPCR) analysis of <italic>ahctf1</italic> mRNA levels in pooled micro-dissected larval livers (<italic>n</italic> = 3 biological replicates). (<bold>c</bold>) Representative three-dimensional reconstructions of <italic>2-CLiP</italic> and dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larval livers of the indicated <italic>ahctf1</italic> genotype. Scale bar 25 µm. (<bold>d</bold>) Impact of <italic>ahctf1</italic> heterozygosity on liver volume in <italic>2-CLiP</italic> and <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 20). (<bold>e</bold>) Impact of <italic>ahctf1</italic> heterozygosity on liver-to-body mass ratio of adult <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish in the presence or absence of dox treatment (<italic>n</italic> = 10). (<bold>f</bold>) Histological sections of adult male <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish livers of the indicated <italic>ahctf1</italic> genotype and dox treatment, stained with haematoxylin and eosin. In vehicle-treated adults, hepatocytes are densely packed and well differentiated. White arrows point to sections through blood vessels containing red blood cells. Meanwhile, the hepatocytes in dox-treated animals are poorly differentiated and exhibit multiple cytological abnormalities, including pyknotic nuclei (arrowheads) and vacuolation (black arrows). Scale bar 25 µm. (<bold>g</bold>) Western blot of Ras and Gapdh protein signals in total input lysates (50 μg) of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae of the indicated <italic>ahctf1</italic> genotype and dox treatment. (<bold>h</bold>) Western blot of active Ras-GTP protein signals in lysates following active Ras pull-down.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title><xref ref-type="fig" rid="fig1">Figure 1b</xref>: Heterozygous <italic>ahctf1</italic> mRNA expression in the livers of doxycycline (dox)-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae, relative to wildtype (WT).</title><p><xref ref-type="fig" rid="fig1">Figure 1d</xref>: Liver volume [µm<sup>3</sup>] of <italic>2-CLiP</italic> and <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype. <xref ref-type="fig" rid="fig1">Figure 1e</xref>: Liver/body mass ratio (%) of adult male and female <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish with and without dox treatment: role of <italic>ahctf1</italic> genotype.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig1-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title><xref ref-type="fig" rid="fig1">Figure 1g</xref>: Uncropped unlabelled western blot.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig1-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata3"><label>Figure 1—source data 3.</label><caption><title><xref ref-type="fig" rid="fig1">Figure 1g</xref>: Uncropped western blot (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig1-data3-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata4"><label>Figure 1—source data 4.</label><caption><title><xref ref-type="fig" rid="fig1">Figure 1h</xref>: Uncropped unlabelled western blot.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig1-data4-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig1sdata5"><label>Figure 1—source data 5.</label><caption><title><xref ref-type="fig" rid="fig1">Figure 1h</xref>: Uncropped western blot (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig1-data5-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Analysis of RNAseq data from livers micro-dissected from <italic>TO(kras<sup>G12V</sup>)<sup>+/+</sup></italic> (wildtype, WT) and dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae reveals patterns of differential gene expression that recapitulate human hepatocellular carcinoma (HCC).</title><p>(<bold>a</bold>) Mean difference plot of differentially expressed genes (DEGs) between <italic>TO(kras<sup>G12V</sup>)<sup>+/+</sup></italic> (WT) and dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae. Each point represents the average expression of a gene (log counts per million) plotted on the <italic>x</italic>-axis and its log-fold change (<italic>y</italic>-axis). Red circles represent 6290 significantly upregulated genes in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers (FDR &lt;0.05), compared to WT livers. Blue circles represent 6398 significantly downregulated genes and black circles represent 8337 genes that are not significantly changed. (<bold>b</bold>) Heatmap of the DEGs in livers from WT and dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae. Data are expressed as mean ± standard error of the mean (SEM), <italic>n</italic> <underline>&gt; </underline>3. Significance was calculated using a Student’s <italic>t</italic>-test. (<bold>c</bold>) Barcode plot showing positive correlation (roast test p value = 5.00025 × 10<sup>−5</sup>) between the differential gene expression results from the dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers, compared to WT livers, and the hepatocellular carcinoma (HCC) gene expression signature. On the barcode plot, the <italic>t</italic>-statistics analysis from the dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers compared to WT livers are ranked from smallest to largest, left to right. The position of genes in the HCC gene expression signature are marked by vertical bars; red for upregulated genes and blue for downregulated genes. The enrichment worms show the relative enrichment of the vertical bars in each part of the plot. (<bold>d</bold>) Barcode plot showing positive correlation (roast test p value = 5.00025 × 10<sup>−5</sup>) between the differential gene expression analysis from the dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> versus WT livers and a small HCC gene expression signature based on four patient samples containing KRAS G12/G13 mutations. (<bold>e</bold>) Top 10 upregulated KEGG pathways in the livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae, compared to livers of WT larvae. The number of upregulated DEGs and total genes in each pathway are shown for each bar. Log (p) values &gt;1.3 (vertical line) denotes significant enrichment. Raw data have been deposited in the Gene Expression Omnibus under accession number GSE220282.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title><italic>ahctf1</italic> heterozygosity and/or homozygous <italic>tp53</italic> mutation do not impact on body length.</title><p>(<bold>a</bold>) Body length at 7 dpf of <italic>2-CLiP</italic> larvae (not expressing a mutant <italic>kras</italic> transgene) and (<bold>b</bold>) <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (no dox treatment) of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes (<italic>n</italic> ≥ 25). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title><italic>ahctf1</italic> heterozygosity and/or homozygous <italic>tp53</italic> mutation do not impact on liver volume during normal liver development.</title><p>(<bold>a</bold>) Representative three-dimensional reconstructions of <italic>2-CLiP</italic> livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes. Scale bar 25 µm. (<bold>b</bold>) Impact of <italic>ahctf1</italic> heterozygosity and <italic>tp53</italic> mutation on liver volume in <italic>2-CLiP</italic> larvae (<italic>n</italic> ≥ 15). Data are expressed as mean ± standard error of the mean (SEM). Significance was assessed using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig1-figsupp3-v2.tif"/></fig></fig-group></sec><sec id="s2-2"><title><italic>ahctf1</italic> heterozygosity reduces liver overgrowth in a zebrafish model of <italic>kras<sup>G12V</sup>-</italic>driven HCC</title><p>We investigated the requirement for Elys in this in vivo cancer setting by introducing a mutant <italic>ahctf1</italic> allele (<italic>flo</italic><sup>ti262</sup>) (<xref ref-type="bibr" rid="bib9">Chen et al., 1996</xref>) into the genome of the <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> model. This produced a 57% reduction in <italic>ahctf1</italic> mRNA expression in <italic>ahctf1<sup>+/−</sup></italic> larvae at 7 dpf, compared to larvae expressing WT <italic>ahctf1</italic> (<xref ref-type="fig" rid="fig1">Figure 1b</xref>). This is consistent with the nonsense mutation in <italic>ahctf1</italic><sup>ti262</sup> triggering nonsense mediated decay of mRNA transcribed from the affected allele, rather than it being translated and expressed as a truncated Elys protein. As a control for our experiments, we used another transgenic line, denoted <italic>2-CLiP</italic> (2-<underline>C</underline>olour <underline>Li</underline>ver <underline>P</underline>ancreas), in which hepatocytes express dsRed fluorescence constitutively but no oncogenic transgene (<xref ref-type="bibr" rid="bib27">Korzh et al., 2008</xref>). On this background, heterozygous (HET) <italic>ahctf1<sup>ti262</sup></italic> zebrafish develop normally (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2a</xref>), reach sexual maturity, and exhibit a normal lifespan, as do HET <italic>ahctf1</italic> mice (<xref ref-type="bibr" rid="bib40">Okita et al., 2004</xref>). Similarly, hepatocytes on the <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> background receiving no dox treatment developed normally (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2b</xref>). Mean liver volume in control <italic>2-CLiP</italic> larvae at 7 dpf was 1.95 × 10<sup>6</sup> ± 4.99 × 10<sup>4</sup> μm<sup>3</sup> and was unaffected by <italic>ahctf1</italic> genotype (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3a, b</xref>).</p><p>Dox-induced expression of oncogenic Kras<sup>G12V</sup> in the <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> model, produced a striking (4-fold) increase in liver volume (7.97 × 10<sup>6</sup> ± 1.21 × 10<sup>5</sup> μm<sup>3</sup>) over the 5 days of dox treatment (<xref ref-type="fig" rid="fig1">Figure 1c, d</xref>). Remarkably, liver volume was pared back to 5.92 × 10<sup>6</sup> ± 8.83 × 10<sup>4</sup> µm<sup>3</sup> in <italic>ahctf1</italic> HETS, equating to a 35% reduction in excess liver volume. <italic>ahctf1</italic> heterozygosity also reduced liver enlargement in <italic>kras<sup>G12V</sup></italic>-expressing adult zebrafish. To induce HCC in these experiments, sexually mature zebrafish aged 3 months post-fertilisation were treated with dox (final concentration 20 mg/L) for 7 days with fresh water and dox administered daily. After 7 days, the impact of forced <italic>kras<sup>G12V</sup></italic> expression was assessed in both male and female adults by measuring the mass of the liver and expressing this as a percentage of the total mass of the animal prior to liver dissection (<xref ref-type="fig" rid="fig1">Figure 1e</xref>). Compared to vehicle-treated animals, we found that dox induction of <italic>kras<sup>G12V</sup></italic> expression produced a robust (9-fold) increase in liver mass expressed as a percentage of total body mass of male zebrafish expressing WT <italic>ahctf1</italic>. This ratio was reduced by 28% in <italic>ahctf1</italic> HETS and we obtained similar results with females (<xref ref-type="fig" rid="fig1">Figure 1e</xref>). Histological sections of livers from vehicle-treated <italic>ahctf1<sup>+/+</sup>; TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> males stained with haematoxylin and eosin (H&amp;E) revealed an orderly arrangement of polygonal hepatocytes interspersed with blood vessels containing red blood cells. In the absence of dox, this appearance was unaffected by <italic>ahctf1</italic> genotype (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, top row). In contrast, dox-treated <italic>ahctf1<sup>+/+</sup>; TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic>-expressing male livers exhibited severely disrupted architecture, and a general loss of hepatocyte organisation (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, bottom left). Hepatocytes were generally poorly differentiated and some exhibited features such as pyknotic nuclei, condensed nucleoli, and vacuolation (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, bottom left). Sections of <italic>kras<sup>G12V</sup></italic>-expressing livers from <italic>ahctf1</italic> HETS showed hepatocytes with improved nuclear integrity and less vacuolation (<xref ref-type="fig" rid="fig1">Figure 1f</xref>, bottom right). These data show that in both larval and adult <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic>-expressing zebrafish, a modest (50%) decrease in <italic>ahctf1</italic> mRNA expression exerts a robust and selective reduction in hepatocyte hyperplasia and liver overgrowth.</p></sec><sec id="s2-3"><title>Level of activated (GTP-bound) Ras in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae is unaffected by <italic>ahctf1</italic> heterozygosity</title><p>To determine how heterozygous <italic>ahctf1</italic> mRNA expression restricts mutant <italic>kras</italic>-driven liver overgrowth, we investigated whether the Elys protein could interfere with the activation of Kras<sup>G12V</sup> directly. To do this, we first quantitated the abundance of the EGFP-Kras<sup>G12V</sup> protein using western blot analysis. Dox treatment markedly increased the abundance of the EGFP-Kras<sup>G12V</sup> protein in lysates of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae compared to vehicle-treated larvae (<xref ref-type="fig" rid="fig1">Figure 1g</xref>), and this was unaffected by <italic>ahctf1</italic> genotype. We then used an active (GTP-bound) Ras pull-down assay to isolate the active GTP-bound fraction of Ras proteins in lysates of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae, followed by western blot analysis (<xref ref-type="bibr" rid="bib1">Baker and Rubio, 2021</xref>). In vehicle-treated zebrafish larvae, signals corresponding to GTP-bound endogenous Ras proteins were weak, whereas lysates from dox-treated larvae gave robust signals corresponding to activated EGFP-Kras<sup>G12V</sup> proteins. The intensity of these signals was not affected by <italic>ahctf1</italic> genotype (<xref ref-type="fig" rid="fig1">Figure 1h</xref>). Thus, the impact of heterozygous <italic>ahctf1</italic> mutation on the growth, proliferation, and survival of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> expressing hepatocytes did not occur by directly or indirectly interfering with the production of GTP-bound Ras proteins.</p></sec><sec id="s2-4"><title><italic>ahctf1</italic> heterozygosity disrupts the abundance of NPCs in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes</title><p>Having demonstrated that <italic>ahctf1</italic> heterozygosity restricts <italic>kras<sup>G12V</sup></italic>-driven liver enlargement, we sought to understand the biological mechanisms underlying this. As previously mentioned, Elys is a multifunctional protein with several roles in the cell cycle (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). We started by examining whether its canonical role in post-mitotic nuclear pore assembly (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1a, b</xref>) was disrupted. To measure the abundance and distribution of NPCs, we stained thick sections of larval livers (200 μm), with an antibody (mAb414) that recognises FG-repeat NUPs (NUP358, 214, 153, and 62) in mature NPCs. Using Airyscan confocal laser-scanning microscopy, we showed that hepatocytes not carrying the <italic>TO(kras<sup>G12V</sup></italic>) transgene (denoted <italic>TO(kras)<sup>+/+</sup></italic>), exhibit fluorescent puncta corresponding to NPCs at the nuclear rim with negligible staining in the cytoplasm, a pattern that was unaffected by <italic>ahctf1</italic> genotype (<xref ref-type="fig" rid="fig2">Figure 2a</xref>; left two columns). In dox-treated larvae harbouring the <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> transgene, fluorescence intensity was markedly increased (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, third column) and there was an increase in the ratio of nuclear:cytoplasmic staining (<xref ref-type="fig" rid="fig2">Figure 2b</xref>). By comparison, fluorescence intensity at the nuclear rim was diminished in <italic>ahctf1</italic> HETS, concomitant with the appearance of fluorescent puncta in the cytoplasm (<xref ref-type="fig" rid="fig2">Figure 2a</xref>, fourth column; arrows) and a significant reduction in the ratio of nuclear:cytoplasmic fluorescence intensity (<xref ref-type="fig" rid="fig2">Figure 2b</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title><italic>ahctf1</italic> heterozygosity disrupts the density of nuclear pore complexes and reduces nuclear volume in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes.</title><p>(<bold>a</bold>) Representative Airyscan imaging of liver sections stained with mAb414 (white) marking FG-NUPs, Hoechst 33342 (cyan) marking DNA, and rhodamine phalloidin (magenta) marking the F-actin cytoskeleton in non-<italic>TO(kras<sup>G12V</sup></italic>)-expressing cells and EGFP-Kras<sup>G12V</sup> (magenta) marking the cell membrane in dox-treated <italic>TO(kras<sup>G12V</sup></italic>)-expressing cells of the indicated <italic>ahctf1</italic> and <italic>TO(kras<sup>G12V</sup></italic>) genotypes. Arrows in right-hand panel point to mAb414/FG-nucleoporin staining in the cytoplasm. Scale bar 2 µm. (<bold>b</bold>) Quantification of mean nuclear/cytoplasmic fluorescence intensity of mAb414 staining after 3D segmentation and morphological filtering of nuclear and cytoplasmic areas (<italic>n</italic> &gt; 18). (<bold>c</bold>) Representative Airyscan images of mAb414 staining at the nuclear surface of sections of the indicated <italic>ahctf1</italic> and <italic>TO(kras<sup>G12V</sup></italic>) genotype. Scale bar 1 µm. (<bold>d</bold>) Quantification of nuclear pore density (<italic>n</italic> ≥ 25). (<bold>e</bold>) Quantification of nuclear volume (<italic>n</italic> ≥ 25). Data are expressed as mean ± standard error of the mean (SEM). Significance was assessed using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title><xref ref-type="fig" rid="fig2">Figure 2b</xref>: Ratio of nuclear to cytoplasmic intensity of mAb414 immunostaining in livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype.</title><p><xref ref-type="fig" rid="fig2">Figure 2d</xref>: Abundance of nuclear pores per µm<sup>2</sup> in livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype. <xref ref-type="fig" rid="fig2">Figure 2e</xref>: Mean volume of nuclei per µm<sup>3</sup> in dox-treated livers of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig2-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>ELYS (encoded by <italic>AHCTF1</italic>) is a protein component of nuclear pore complexes (NPCs) with multiple functions during the cell cycle.</title><p>(<bold>a–c</bold>) Through its canonical role in nuclear pore re-assembly at the end of mitosis, ELYS restores nucleocytoplasmic trafficking of molecules required for cell cycle progression, including mRNAs and cyclin-dependent kinases (CDKs). (<bold>d–f</bold>) ELYS plays an active role in genome regulation through its direct interactions with components of large molecular machineries including chromatin remodellers that favour transcription and components of the DNA replication origin licensing system. (<bold>g, h</bold>) Dissolution of the nuclear envelope and NPCs prepares the cell for mitosis during which time ELYS relocalises to kinetochores where it contributes to microtubule attachment and spindle formation.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig2-figsupp1-v2.tif"/></fig></fig-group><p>To determine the abundance of NPCs, we analysed the pattern and density of fluorescent puncta observed at the nuclear surface of non-<italic>kras<sup>G12V</sup></italic> expressing hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2c</xref>; left two columns). The induced expression of the <italic>kras<sup>G12V</sup></italic> transgene in the presence of WT <italic>ahctf1</italic> resulted in 59% more fluorescent puncta/NPCs at the nuclear surface of hyperplastic hepatocytes (<xref ref-type="fig" rid="fig2">Figure 2c, d</xref>; third column). These signals were reduced by 21% in <italic>ahctf1</italic> HETS (<xref ref-type="fig" rid="fig2">Figure 2c, d</xref>; fourth column). Induced <italic>kras<sup>G12V</sup></italic> expression also produced a 28% increase in nuclear volume compared to non-<italic>kras<sup>G12V</sup></italic>-expressing cells (<xref ref-type="fig" rid="fig2">Figure 2e</xref>), and this increase in size was reduced to 13% in <italic>ahctf1</italic> HETS. We infer from these data that hyperplastic hepatocytes expressing the <italic>kras<sup>G12V</sup></italic> oncogene require highly efficient rates of nucleocytoplasmic transport to support their rapid proliferation, which they fulfil by increasing NPC density and the size of their nuclei. This adaptation required a full complement of <italic>ahctf1</italic> expression, suggesting non-oncogene addiction to <italic>ahctf1</italic>. We found that in hyperplastic hepatocytes that were heterozygous for <italic>ahctf1</italic> this adaptation was partially restricted, creating a condition likely to amplify oncogenic stress.</p></sec><sec id="s2-5"><title><italic>ahctf1</italic> heterozygosity impairs mitotic spindle assembly and chromosome segregation in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes</title><p>Next, we examined the impact of reduced Elys expression on spindle formation and chromosome segregation during mitosis (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1g and h</xref>). We assessed these features in cryosections of liver using α-tubulin and 4′,6-diamidino-2-phenylindole (DAPI) to stain microtubules and chromatin, respectively. Metaphase cells in <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers exhibited normal bipolar spindle formation followed by complete chromosome segregation during anaphase (<xref ref-type="fig" rid="fig3">Figure 3a</xref>). In contrast, metaphase cells in <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes displayed abnormal multipolar spindles and misaligned chromosomes (<xref ref-type="fig" rid="fig3">Figure 3b</xref>). Proper chromosome segregation was disrupted with multiple anaphase bridges formed. While the number of cells observed at different mitotic stages was similar in <italic>ahctf1<sup>+/+</sup></italic> and <italic>ahctf1<sup>+/−</sup></italic> (<xref ref-type="fig" rid="fig3">Figure 3c</xref>), mitotic abnormalities were observed in 50% of <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes during metaphase and anaphase but not at all in <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes (<xref ref-type="fig" rid="fig3">Figure 3d</xref><italic>)</italic>. These data are consistent with hyperplastic hepatocytes requiring a full complement of <italic>ahctf1</italic> expression to maintain rapid rounds and integrity of mitosis, and provide another facet of non-oncogene addiction to <italic>ahctf1</italic> that is likely to contribute to oncogenic stress.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title><italic>ahctf1</italic> heterozygosity impairs mitotic spindle assembly and chromosome segregation in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes.</title><p>(<bold>a</bold>) Representative Airyscan imaging of liver cryosections stained with α-tubulin antibody (magenta) marking spindle microtubules and DAPI (cyan) marking DNA in mitotic cells of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae on a wildtype <italic>ahctf1<sup>+/+</sup></italic> background. (<bold>b</bold>) Mitotic cells in liver cryosections of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae that are heterozygous for <italic>ahctf1<sup>+/−</sup></italic> exhibit multiple defects, including multipolar spindles, misaligned chromosomes, and anaphase bridges (arrows). Scale bar 2 µm. (<bold>c</bold>) Distribution of cells observed at different mitotic stages (<italic>n</italic> = 92 livers, 326 mitotic cells). (<bold>d</bold>) Quantification of the percentage of mitotic hepatocytes exhibiting an aberrant phenotype (<italic>n</italic> = 14–57). Significance was assessed using a Chi-square test.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title><xref ref-type="fig" rid="fig3">Figure 3c</xref>: Number of cells at different stages of mitosis in livers of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype.</title><p><xref ref-type="fig" rid="fig3">Figure 3d</xref>: Percentage of mitotic cells expressing an aberrant phenotype in livers of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig3-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig3-v2.tif"/></fig></sec><sec id="s2-6"><title><italic>ahctf1</italic> heterozygosity causes DNA damage and accumulation of Tp53 protein in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes</title><p>Other features of oncogene-induced stress in response to robust and persistent overexpression of RAS oncoproteins include stalled DNA replication, DNA damage, and genome instability. To determine whether expression of <italic>kras<sup>G12V</sup></italic> causes DNA damage in our model, we stained cryosections of larval livers with DAPI and γ-H2AX, which is a sensitive marker for stalled DNA replication forks and DNA double-strand breaks (<xref ref-type="bibr" rid="bib48">Rogakou et al., 1998</xref>). We found that 1% of <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocyte nuclei were positive for γ-H2AX (<xref ref-type="fig" rid="fig4">Figure 4a, c</xref>), compared to 6% in the nuclei of <italic>ahctf1</italic> HETS (<xref ref-type="fig" rid="fig4">Figure 4b, c</xref>).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title><italic>ahctf1</italic> heterozygosity causes DNA damage and accumulation of Tp53 protein in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes.</title><p>(<bold>a</bold>) Representative Airyscan imaging of cryosections of liver from dox-treated <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae stained with γ-H2AX antibody (white) marking DNA double-strand breaks, DAPI (cyan) marking DNA and EGFP-Kras<sup>G12V</sup> (magenta) marking the cell membrane. Scale bar 5 µm. (<bold>a’</bold>) Inset of γ-H2AX-positive nuclei in <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes. Scale bar 2 µm. (<bold>b</bold>) Representative images of cryosections of liver from dox-treated <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae. Scale bar 5 µm. (<bold>b’</bold>) Inset of γ-H2AX-positive nuclei in cryosections of liver from <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae. Scale bar 2 µm. (<bold>c</bold>) Quantification of the percentage of hepatocytes positive for γ-H2AX (<italic>n</italic> ≥ 31). (<bold>d</bold>) Representative western blot of Tp53 protein signals in lysates of <italic>TO(kras<sup>G12V</sup></italic>) larvae of the indicated <italic>ahctf1</italic> genotype. (<bold>e</bold>) Quantification of Tp53 protein levels normalised by reference to the Gapdh loading control (<italic>n</italic> = 3 independent experiments). (<bold>f</bold>) Representative three-dimensional reconstructions of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes. Scale bar 25 µm. (<bold>g</bold>) Impact of <italic>ahctf1</italic> heterozygosity and homozygous <italic>tp53</italic> mutation on liver volume in <italic>2-CLiP</italic> and <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 20). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a Student’s <italic>t</italic>-test or one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title><xref ref-type="fig" rid="fig4">Figure 4c</xref>: Percentage of hepatocytes positive for γ-H2AX immunostaining in livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype.</title><p><xref ref-type="fig" rid="fig4">Figure 4e</xref>: Quantitation of Tp53 protein intensity in western blots of lysates from <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> genotype. <xref ref-type="fig" rid="fig4">Figure 4g</xref>: Quantitation of liver volume (µm<sup>3</sup>) of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>tp53</italic> mutation.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4—source data 2.</label><caption><title><xref ref-type="fig" rid="fig4">Figure 4d</xref>: Uncropped unlabelled western blot.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig4-data2-v2.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4—source data 3.</label><caption><title><xref ref-type="fig" rid="fig4">Figure 4d</xref>: Uncropped western blot (labelled).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-73407-fig4-data3-v2.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig4-v2.tif"/></fig><p>In the presence of WT Tp53, DNA damage is limited by activation of Tp53 transcription-dependent pathways that can perform DNA damage repair, and, if necessary, induce cell cycle arrest, senescence, and/or apoptosis. To determine whether the increase in DNA damage that occurred in our model in response to <italic>ahctf1</italic> heterozygosity stimulated Tp53 accumulation, we measured the levels of Tp53 protein in pooled lysates of micro-dissected <italic>kras<sup>G12V</sup></italic>-expressing livers, <italic>kras<sup>G12V</sup></italic>-nonexpressing livers and the larval remains after the dissection (<xref ref-type="fig" rid="fig4">Figure 4d, e</xref>). No Tp53 signal was obtained from non-<italic>kras<sup>G12V</sup></italic>-expressing livers, or the body remains after liver removal. However, we detected a weak Tp53 signal in extracts of dox-treated <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers, consistent with induced <italic>kras<sup>G12V</sup></italic> expression causing mild cellular stress. This low level of stress was amplified significantly in heterozygous <italic>ahctf1</italic> livers, where we obtained a strong (&gt;3.5-fold) increase in the intensity of the Tp53 signal (<xref ref-type="fig" rid="fig4">Figure 4e</xref>), which correlated well with the higher density of γ-H2AX staining.</p><p>To test whether Tp53 accumulation was responsible for limiting liver volume in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae, we introduced the zebrafish <italic>tp53<sup>M214K</sup></italic> allele encoding a transactivation dead Tp53 variant (<xref ref-type="bibr" rid="bib3">Berghmans et al., 2005</xref>). Abrogating Tp53 function by homozygous expression of this allele (denoted <italic>tp53<sup>m/m</sup></italic>) in <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae increased liver volume by 50%, to 12.5 × 10<sup>6</sup> ± 1.10 × 10<sup>5</sup> μm<sup>3</sup>, compared to livers on a WT (<italic>tp53<sup>+/+</sup></italic>) background (<xref ref-type="fig" rid="fig4">Figure 4f, g</xref>), demonstrating that Tp53 function normally places great restraint on the growth of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers in this model. <italic>ahctf1</italic> heterozygosity combined with loss of Tp53 function also produced an increase in liver volume by 50% compared to <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers on a WT Tp53 background. Comparing the volume of <italic>ahctf1</italic> HET livers and WT <italic>ahctf1</italic> livers on a Tp53 mutant background, showed that heterozygous <italic>ahctf1</italic> still achieved a reduction in liver volume, albeit significantly less than in the presence of WT Tp53.</p></sec><sec id="s2-7"><title><italic>ahctf1</italic> heterozygosity amplifies cell death of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes in the presence and absence of WT Tp53</title><p>The tumour suppressive properties of Tp53 lie in its capacity to activate the transcription of genes that participate in processes that restrict tumour growth, including cell cycle arrest, senescence, apoptosis, DNA repair, and metabolic adaptation. To test whether disruption of these processes contributed to the reduction in liver volume we observe between WT and heterozygous <italic>ahctf1</italic> larvae, we first looked at apoptosis. To do this, we introduced an apoptosis reporter transgene, Tg(<italic>actb2:SEC-Hsa.ANXA5-mKate2,cryaa:mCherry</italic>)<sup>uq24rp</sup> (hereafter denoted <italic>Annexin 5-mKate</italic>) into the HCC model. This transgene constitutively expresses a fusion protein comprising Annexin 5 and the far-red fluorophore mKate (<xref ref-type="bibr" rid="bib19">Hall et al., 2019</xref>). The protein generates discrete fluorescent puncta in cells undergoing apoptosis by binding to phosphatidylserine molecules that become accessible to Annexin 5 binding when the plasma membrane breaks down during apoptosis. The abundance of Annexin 5 fluorescent puncta was 1.5 puncta per 10<sup>−5</sup> μm<sup>3</sup> in the livers of WT Tp53, <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae and this value increased by 3.5-fold (5.2 puncta per 10<sup>−5</sup> μm<sup>3</sup>) on a heterozygous <italic>ahctf1</italic> background (<xref ref-type="fig" rid="fig5">Figure 5a</xref>, left two columns, <xref ref-type="fig" rid="fig5">Figure 5b</xref>). We saw a comparable increase in the number of apoptotic cells in heterozygous <italic>ahctf1</italic> livers when we used the cleaved (active) form of caspase-3 as an alternative marker of apoptosis (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title><italic>ahctf1</italic> heterozygosity amplifies cell death in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes in the presence and absence of Tp53.</title><p>(<bold>a</bold>) Representative maximum intensity projection images of Annexin 5-mKate fluorescence (white puncta), indicating cells undergoing apoptosis in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes. Scale bar 25 µm. (<bold>b</bold>) Quantification of the density of Annexin 5 fluorescent foci in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes (<italic>n</italic> ≥ 11). (<bold>c</bold>) RT-quantitative PCR (RT-qPCR) analysis of the specified mRNAs in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> micro-dissected livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes (<italic>n</italic> = 3 biological replicates). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title><xref ref-type="fig" rid="fig5">Figure 5b</xref>: Quantitation of Annexin 5-mKate fluorescence per volume (µm<sup>3</sup>) in livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>tp53</italic> mutation.</title><p><xref ref-type="fig" rid="fig5">Figure 5c</xref>: Multiple mRNA expression analyses by RT-quantitative PCR (RT-qPCR) of micro-dissected livers from dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>tp53</italic> mutation.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig5-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title><italic>ahctf1</italic> heterozygosity increases the percentage of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes expressing the cleaved, active form of caspase-3.</title><p>(<bold>a</bold>) Representative Airyscan images of <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> liver cryosections stained with an antibody specific for the cleaved (active) form of caspase-3 (magenta) marking apoptosis and DAPI (cyan) marking DNA. Scale bar 5 µm. (<bold>b</bold>) Cryosections of liver from dox-treated <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae reveal hepatocytes exhibiting cleaved caspase-3 staining and fragmented nuclei with condensed chromatin. Scale bar 5 µm. (<bold>b’</bold>) Inset showing higher magnification image of cleaved caspase-3-positive hepatocytes in livers from <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae. Scale bar 2 µm. (<bold>c</bold>) Quantification of the percentage of cells positive for active cleaved caspase-3 (<italic>n</italic> = 28 liver sections). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a Student’s <italic>t</italic>-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig5-figsupp1-v2.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title><italic>ahctf1</italic> heterozygosity reduces <italic>ahctf1</italic> mRNA expression and increases expression of <italic>∆113tp53.</italic></title><p>(<bold>a</bold>) RT-quantitative PCR (RT-qPCR) analysis of <italic>ahctf1</italic> and <italic>tp53</italic> mRNA expression and (<bold>b</bold>) <italic>∆113tp53</italic> (target of Tp53) mRNA expression in micro-dissected livers of dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes (<italic>n</italic> = 3 biological replicates). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig5-figsupp2-v2.tif"/></fig></fig-group><p>To determine whether Tp53 accumulation played a role in this cell death, we measured the density of Annexin 5 puncta in the absence of functional Tp53. Compared to those expressing WT Tp53 (1.5 puncta per 10<sup>−5</sup> μm<sup>3</sup>), Annexin 5 puncta were relatively sparse (0.13 puncta per 10<sup>−5</sup> μm<sup>3</sup>) in Tp53-deficient livers on a <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> background. This robust (11.3-fold) reduction in the density of Annexin 5 foci indicates that the death of hepatocytes in <italic>ahctf1</italic> WT, <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers is normally kept in check by Tp53 (<xref ref-type="fig" rid="fig5">Figure 5a, b</xref>). Turning to <italic>ahctf1</italic> HETS, the density of Annexin 5 puncta on a <italic>tp53<sup>m/m</sup></italic> background was 2.3 puncta per 10<sup>−5</sup> μm<sup>3</sup>, less than half the number of puncta (5.2 per 10<sup>−5</sup> μm<sup>3</sup>) on a WT Tp53 background (<xref ref-type="fig" rid="fig5">Figure 5a, b</xref>). The number of hepatocytes undergoing apoptosis on a Tp53-deficient background remained higher in heterozygous <italic>ahctf1</italic> larvae compared to <italic>ahctf1</italic> WT larvae, albeit it was much reduced compared to that observed in the presence of WT Tp53.</p><p>To determine whether these responses were tied to the expression of pro-apoptotic Tp53 target genes in <italic>kras<sup>G12V</sup></italic>-driven hepatocytes, we used RT-quantitative PCR (RT-qPCR) analysis of pooled micro-dissected livers (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). The abundance of <italic>tp53</italic> mRNA was unaffected by <italic>ahctf1</italic> heterozygosity (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2a</xref>), which was to be expected because the accumulation of Tp53 protein is regulated post-translationally. However, we could infer that Tp53 transcription was activated by <italic>ahctf1</italic> heterozygosity by the expression of the canonical Tp53 target genes, <italic>mdm2</italic> and <italic>Δ113tp53</italic>, which were upregulated by 4.7-fold (<xref ref-type="fig" rid="fig6">Figure 6c</xref>) and &gt;6-fold, respectively (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2b</xref>), compared to when <italic>ahctf1</italic> was WT.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title><italic>ahctf1</italic> heterozygosity restricts DNA replication in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes in the presence and absence of Tp53.</title><p>(<bold>a</bold>) Representative maximum intensity projection images of EdU incorporation (white puncta) into <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes. Scale bar 25 µm. (<bold>b</bold>) Quantification of the percentage of EdU-positive nuclei per Hoechst 33342-positive nuclei (<italic>n</italic> ≥ 25). (<bold>c</bold>) Impact of <italic>ahctf1</italic> heterozygosity and homozygous <italic>tp53</italic> mutation on liver volume in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 17). (<bold>d</bold>) RT-quantitative PCR (RT-qPCR) analysis of mRNA expression of the cell cycle regulators, <italic>cdkn1a</italic> and <italic>cdkn2a/b</italic> and (<bold>e</bold>) <italic>tp63</italic> and <italic>tp73</italic> expression in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> micro-dissected livers of the indicated <italic>ahctf1</italic> and <italic>tp53</italic> genotypes (<italic>n</italic> = 3 biological replicates). Data are expressed as mean ± standard error of the mean (SEM). Significance was assessed using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title><xref ref-type="fig" rid="fig6">Figure 6d</xref>: <italic>cdkna1</italic> and cdkna2a/b mRNA expression analyses by RT-quantitative PCR (RT-qPCR) of micro-dissected livers from doxycycline (dox)-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>tp53</italic> mutation.</title><p><xref ref-type="fig" rid="fig6">Figure 6e</xref>: <italic>p63</italic> and <italic>p73</italic> mRNA expression analyses by RT-qPCR of micro-dissected livers from doxycycline (dox)-treated <italic>TO(kras<sup>G12V</sup>) <sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>tp53</italic> mutation.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig6-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title><italic>ahctf1</italic> heterozygosity results in activation of a tp53 transcriptional programme in dox-treated adult male <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish.</title><p>(<bold>a</bold>) RT-quantitative PCR (RT-qPCR) analysis of <italic>ahctf1</italic>. (<bold>b, c</bold>) Expression of <italic>tp53</italic> mRNA and Tp53 target genes. (<bold>d</bold>) mRNA expression of cell death and (<bold>e</bold>) cell cycle regulators in the livers of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> adult zebrafish of the indicated <italic>ahctf1</italic> genotype and dox treatment (<italic>n</italic> = 3 biological replicates). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig6-figsupp1-v2.tif"/></fig></fig-group><p>We then examined the expression levels of Bcl2 family genes that regulate mitochondrial apoptosis including mRNAs encoding the six BH3-only apoptosis effector proteins, Pmaip1 (aka Noxa) and Bbc3 (aka Puma), Bim, Bid, Bik, and Bad, and the pro-apoptotic executioner protein, Bax (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). All were significantly increased in the livers of <italic>ahctf1</italic> HETS compared to WT <italic>ahctf1</italic> livers. The most marked upregulation was observed with the classical Tp53 transcriptional targets, <italic>pmaip1</italic>, <italic>bbc3</italic>, and <italic>bax</italic> (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). In contrast, transcripts encoding the pro-survival proteins, Bcl2 and Bclxl, were significantly downregulated by <italic>ahctf1</italic> heterozygosity (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). In the absence of Tp53 function, <italic>ahctf1</italic> heterozygosity produced more modest increases in the expression of the pro-apoptotic transcripts and smaller decreases in the expression of the pro-survival <italic>bcl2</italic> and <italic>bclxl</italic> genes (<xref ref-type="fig" rid="fig5">Figure 5c</xref>). We surmise from these data that <italic>ahctf1</italic> heterozygosity contributes to a reduction in liver overgrowth in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae by activating a largely Tp53-dependent transcriptional programme that promotes apoptosis.</p></sec><sec id="s2-8"><title><italic>ahctf1</italic> heterozygosity restricts DNA replication in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes</title><p>To determine whether DNA replication and cell cycle progression were affected by <italic>ahctf1</italic> heterozygosity (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1c–e</xref>), we used an EdU incorporation assay to identify the number of DNA replicating cells in S-phase (<xref ref-type="fig" rid="fig6">Figure 6a</xref>). We found that 32% of hyperplastic hepatocytes were positive for EdU in <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae on a WT Tp53 background (<xref ref-type="fig" rid="fig6">Figure 6b</xref>) and this abundance was reduced to 22% of hepatocytes in <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). To determine whether Tp53 played a role in the reduced frequency of cells in S-phase, we repeated the experiment in Tp53-deficient larvae. This resulted in a striking increase in the number of cells in S-phase whereby 63% of hepatocytes were EdU positive in WT <italic>ahctf1</italic> larvae, and 53% of hepatocytes were EdU positive in <italic>ahctf1</italic> HETS (<xref ref-type="fig" rid="fig6">Figure 6b</xref>). These data show that <italic>ahctf1</italic> heterozygosity reduces the number of cells in S-phase by a mechanism that largely depends on the availability of WT Tp53. The changes in EdU incorporation between hepatocytes of different <italic>ahctf1</italic> and <italic>tp53</italic> genotypes were accompanied by corresponding changes in liver volume (<xref ref-type="fig" rid="fig6">Figure 6c</xref>).</p><p>Next, we determined whether the expression of Tp53-dependent negative cell cycle regulators was involved in the reduced number of hepatocytes in S-phase we observed in <italic>ahctf1</italic> HETS. We saw a 3-fold increase in the expression of <italic>cdkn1a</italic> and a 2.5-fold increase in the expression of <italic>cdkn2a/b</italic> in <italic>ahctf1</italic> HET larvae compared to larvae that were WT for <italic>ahctf1</italic> (<xref ref-type="fig" rid="fig6">Figure 6d</xref>). The upregulation of <italic>cdkna1</italic> expression in <italic>ahctf1</italic> HETS was partially reduced by Tp53 deficiency, suggesting that the regulation of <italic>cdkna2</italic> expression was largely, but not completely, Tp53 dependent. In contrast, the upregulation of <italic>cdkna2a/b</italic> was entirely lost in <italic>ahctf1</italic> HETS, showing that in this setting, <italic>cdkna2a/b</italic> upregulation was dependent on the availability of functional Tp53 (<xref ref-type="fig" rid="fig6">Figure 6d</xref>).</p><p>We also found that mRNAs encoding the Tp53 family members, Tp63 and Tp73 were upregulated by 3.0- and 2.3-fold, respectively, in <italic>ahctf1</italic> HET livers, compared to WT <italic>ahctf1</italic> livers, in the presence of WT Tp53 (<xref ref-type="fig" rid="fig6">Figure 6e</xref>). Interestingly, in the absence of WT Tp53 (<xref ref-type="fig" rid="fig6">Figure 6e</xref>), <italic>ahctf1</italic> heterozygosity caused a further, albeit mild, increase in the expression of <italic>tp63</italic> and <italic>tp73</italic>. Since <italic>tp63</italic> and <italic>tp73</italic> are not direct Tp53 target genes, this raises the possibility that elevated <italic>tp63</italic> and <italic>tp73</italic> expression may contribute modest Tp53-independent roles to the inhibition of liver overgrowth, activation of apoptosis and impaired cell cycle progression we observed in response to <italic>ahctf1</italic> heterozygosity. This is plausible because Tp63 and Tp73 have several direct target genes in common with Tp53, including the pro-apoptotic genes, <italic>bbc3</italic>, <italic>pmaip1</italic>, <italic>bim</italic>, and <italic>bax</italic>, and the cell cycle arrest gene, <italic>cdkna1</italic>.</p><p>We also examined the transcriptional profile of pro-apoptotic and cell cycle arrest genes in our adult model of HCC. Looking specifically at the expression of direct Tp53 target genes in response to <italic>ahctf1</italic> heterozygosity, we found that <italic>Δ113tp53</italic>, <italic>mdm2</italic>, <italic>pmaip1</italic>, <italic>bbc3</italic>, <italic>ccgn1</italic>, and <italic>cdkn1a</italic>, were all robustly upregulated in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1a–d</xref>), as was <italic>cdkn2a/b</italic>, which is not a direct Tp53 target (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1e</xref>). These data suggest that Tp53 plays a central role in mediating the reduction in liver enlargement conferred by heterozygous <italic>ahctf1</italic> expression in adult dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers, in agreement with our findings with the larval model of HCC.</p><p>Collectively, our data demonstrate that the reduction in liver overgrowth caused by <italic>ahctf1</italic> heterozygosity in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish is concurrent with the induction of largely Tp53-dependent transcriptional programmes that promote cell cycle arrest and apoptosis. However, we cannot infer from our data whether these two cellular responses are activated simultaneously in individual hepatocytes, or whether they are regulated in a dynamic fashion.</p></sec><sec id="s2-9"><title>Combinatorial targeting of <italic>ahctf1</italic> and <italic>ranbp2</italic> expression blocks liver overgrowth in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae</title><p>To extend our understanding of the role of NUPs in hyperplastic growth, we took advantage of a zebrafish mutant we had previously identified in a transgene assisted ENU-mutagenesis screen (<xref ref-type="bibr" rid="bib38">Ober et al., 2006</xref>), which harboured a nonsense mutation in <italic>ranbp2</italic> (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1a, b</xref>). Like several other digestive organ mutants identified in this screen (<xref ref-type="bibr" rid="bib13">de Jong-Curtain et al., 2009</xref>; <xref ref-type="bibr" rid="bib5">Boglev et al., 2013</xref>; <xref ref-type="bibr" rid="bib33">Markmiller et al., 2014</xref>), <italic>ranbp2<sup>s452</sup></italic> mutants exhibit morphological defects in proliferative compartments, including the intestinal epithelium, craniofacial complex, and eye (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1c, d</xref>). RANBP2 (also known as NUP358) is a major component of the cytoplasmic filaments of NPCs, where it plays a role in nucleocytoplasmic trafficking. Like ELYS, RANBP2 also plays non-canonical roles beyond the NPC, including in mitotic progression and the maintenance of genome integrity (<xref ref-type="bibr" rid="bib24">Joseph et al., 2004</xref>; <xref ref-type="bibr" rid="bib51">Salina et al., 2003</xref>; <xref ref-type="bibr" rid="bib20">Hashizume et al., 2013</xref>).</p><p>Like <italic>ahctf1</italic> heterozygosity, we found that <italic>ranbp2</italic> heterozygosity alone, or in combination with <italic>ahctf1</italic> heterozygosity, had no impact on liver volume in control (<italic>2-CLiP</italic>) larvae (<xref ref-type="fig" rid="fig7">Figure 7a, b</xref>). In <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae that were WT for both <italic>ranbp2 </italic>and <italic>ahctf1</italic>, dox treatment caused a &gt;3.8-fold increase in liver volume. Upon introduction of a single mutation of either <italic>ahctf1</italic> or <italic>ranbp2</italic> into this setting, the excess liver volume was pared back by 38% and 13%, respectively (<xref ref-type="fig" rid="fig7">Figure 7b</xref>). Remarkably, when we measured liver volume in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae that were trans heterozygous for <italic>ranbp2 and ahctf1</italic>, we found a striking, synergistic decrease in liver volume, which by 7 dpf, was not significantly different from that of <italic>2-CLiP</italic> livers, albeit the correct shape of the liver was not completely restored.</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Combinatorial targeting of NUPs and Selinexor treatment restricts liver enlargement in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> hepatocytes.</title><p>(<bold>a</bold>) Representative three-dimensional reconstructions of livers from <italic>2-CLiP</italic> and <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae of the indicated <italic>ahctf1</italic> and <italic>ranbp2</italic> genotypes. Scale bar 25 µm. (<bold>b</bold>) Impact of <italic>ahctf1</italic> heterozygosity and <italic>ranbp2</italic> heterozygosity on liver volume in <italic>2-CLiP</italic> and <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 30). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test. (<bold>c</bold>) Representative three-dimensional reconstructions of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> livers of the indicated <italic>ahctf1</italic> genotype treated with dimethyl sulfoxide (DMSO) or 2.00 µM Selinexor from 5 to 7 dpf. (<bold>d</bold>) Dose-dependent impact of Selinexor treatment on liver volume in <italic>2-CLiP, ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> and <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 20). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated by linear regression analysis.</p><p><supplementary-material id="fig7sdata1"><label>Figure 7—source data 1.</label><caption><title><xref ref-type="fig" rid="fig7">Figure 7b</xref>: Quantitation of liver volume (µm<sup>3</sup>) of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; role of <italic>ahctf1</italic> and <italic>ranbp2</italic> mutation.</title><p><xref ref-type="fig" rid="fig7">Figure 7d</xref>: Quantitation of liver volume (µm<sup>3</sup>) of <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish larvae; impact of <italic>ahctf1</italic> mutation and Selinexor treatment individually and in combination.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig7-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Genetic and morphological characterisation of the <italic>ranbp2</italic> mutant.</title><p>(<bold>a</bold>) Positional cloning of the zebrafish mutant, <italic>s452</italic> identified in a transgene assisted ENU-mutagenesis screen for mutations affecting endodermal organ morphogenesis (<xref ref-type="bibr" rid="bib38">Ober et al., 2006</xref>) using whole-genome sequencing and homozygosity mapping. The genomic region containing the s452 causal mutation is derived exclusively from the initial ENU mutated allele and is defined by increased homozygosity. In <italic>s452</italic> mutants the region of linkage is restricted to a &lt;1.1-kb region on chromosome 9 within the <italic>ranbp2</italic> gene. Plot displays genomic homozygosity across 25 chromosomes, chromosome 9 and the region of linkage. The genome position of <italic>ranbp2</italic> within this region and a schematic diagram of the <italic>ranbp2</italic> transcript with an asterisk denoting the position of the mutation are also shown. (<bold>b</bold>) Sanger sequencing chromatographs reveal a T&gt;A transversion mutation introducing a premature stop codon (TTG&gt;TAG). (<bold>c</bold>) Brightfield images reveal abnormalities in the gross morphology of homozygous mutant <italic>ranbp2</italic> larvae at 7 dpf. <italic>ranbp2<sup>−/</sup></italic><sup>−</sup> larvae exhibit a thinner, flatter intestinal epithelium compared to wildtype and heterozygous <italic>ranbp2</italic> larvae (arrows). They also exhibit a smaller jaw, smaller eyes, failure to inflate the swim bladder and delayed resorption of the yolk. Scale bar 200 µm. (<bold>d</bold>) Sagittal histological sections of 5 dpf <italic>ranbp2</italic> larvae stained with haematoxylin and eosin. Intestinal epithelial cells in <italic>ranbp2<sup>−/−</sup></italic> larvae are smaller, unpolarised and the epithelium lacks characteristic folding, indicative of a proliferation defect.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Combinatorial targeting of <italic>ahctf1</italic> and <italic>ranbp2</italic> restricts <italic>kras<sup>G12V</sup></italic>-driven liver enlargement in adult male zebrafish.</title><p><bold>I</bold>mpact of <italic>ahctf1</italic> heterozygosity and <italic>ranbp2</italic> heterozygosity, individually and in combination, of (<bold>a</bold>) body mass, (<bold>b</bold>) liver mass, and (<bold>c</bold>) liver-to-body-mass ratio of adult male <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish of the indicated dox treatment (<italic>n</italic> = 10). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-figsupp2-v2.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Combinatorial targeting of <italic>ahctf1</italic> and <italic>ranbp2</italic> restricts <italic>kras<sup>G12V</sup></italic>-driven liver enlargement in adult female zebrafish.</title><p><bold>I</bold>mpact of <italic>ahctf1</italic> heterozygosity and <italic>ranbp2</italic> heterozygosity, individually and in combination, on (<bold>a</bold>) body mass, (<bold>b</bold>) liver mass, and (<bold>c</bold>) liver-to-body-mass ratio of adult female <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish of the indicated dox treatment (<italic>n</italic> = 10). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-figsupp3-v2.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>Doxycycline treatment of adult male <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish results in the development of histopathological features of hepatocellular carcinoma (HCC).</title><p>Histological sections of adult male <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish livers of the indicated <italic>ahctf1</italic> and <italic>ranbp2</italic> genotypes, with and without dox treatment, stained with haematoxylin and eosin. In vehicle-treated (no dox) adults, hepatocytes are densely packed and well differentiated. In contrast, the hepatocytes in dox-treated animals expressing oncogenic Kras<sup>G12V</sup> and wildtype (WT) <italic>ahctf1</italic> are poorly differentiated and exhibit multiple cytological abnormalities, including pyknotic nuclei (arrowheads) and vacuolation (arrows). The integrity of cells is partially restored in animals that are heterozygous for either <italic>ahctf1</italic>, <italic>ranbp2</italic>, or a combination of both (bottom row, right panel). Scale bar 25 µm.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-figsupp4-v2.tif"/></fig><fig id="fig7s5" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 5.</label><caption><title>Combination of Selinexor treatment and <italic>ahctf1</italic> heterozygosity reduces liver volume in <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae but has no impact on liver volume in <italic>2-CLiP</italic> larvae.</title><p>Impact of Selinexor treatment (0.10–2.00 µM) on liver volume in (<bold>a</bold>) <italic>ahctf1<sup>+/+</sup>;2-CLiP</italic> larvae (<italic>n</italic> ≥ 40). (<bold>b</bold>) <italic>ahctf1<sup>+/−</sup>;2-CLiP</italic> larvae (<italic>n</italic> ≥ 19). (<bold>c</bold>) <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> ≥ 20). (<bold>d</bold>) <italic>ahctf1<sup>+/−</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae (<italic>n</italic> &gt;20). Data are expressed as mean ± standard error of the mean (SEM). Significance was calculated using a one-way analysis of variation (ANOVA) with Tukey’s multiple comparisons test and linear regression analysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig7-figsupp5-v2.tif"/></fig></fig-group><p>We recapitulated these results in adult male and female <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish. In these experiments, total body mass was unaffected by single mutations in either <italic>ranbp2</italic> or <italic>ahctf1</italic>, or both mutant alleles together, independent of dox treatment (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2a</xref> and <xref ref-type="fig" rid="fig7s3">3a</xref>). However, when liver mass was expressed as a percentage of total body mass, this was reduced by 13% (<italic>ranbp2</italic>) and 28% (<italic>ahctf1</italic>). In adult males carrying both mutations, liver mass expressed as a percentage of total body mass was reduced by 54% (<xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2b and c</xref>). Similar results were obtained in adult females (<xref ref-type="fig" rid="fig7s3">Figure 7—figure supplement 3b, c</xref>). Histological analysis of adult male livers demonstrated that hepatocyte integrity and organisation were improved (fewer abnormal nuclei and cytoplasmic vacuoles) in <italic>ranbp2<sup>+/−</sup>;ahctf1<sup>+/−</sup></italic> HETS (<xref ref-type="fig" rid="fig7s4">Figure 7—figure supplement 4</xref>). Thus, hyperplastic hepatocytes are highly susceptible to combinatorial targeting of NUP function, raising the question of whether this selective vulnerability could be exploited in the clinic.</p></sec><sec id="s2-10"><title>Combining Selinexor treatment with <italic>ahctf1</italic> heterozygosity blocks liver overgrowth in dox-treated <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae</title><p>Selinexor is a selective inhibitor of nuclear export through its interaction with XPO1 (exportin). The drug has received FDA approval for the treatment of refractory or relapsed multiple myeloma and diffuse large B-cell lymphoma and is in clinical trials for several other cancers, including HCC (<xref ref-type="bibr" rid="bib23">Jans et al., 2019</xref>; <xref ref-type="bibr" rid="bib56">Zheng et al., 2014a</xref>), leading us to test the impact of Selinexor treatment in our larval model of HCC. We observed no reduction in liver volume in <italic>2-CLiP</italic> larvae exposed to 0.10–2.00 µM Selinexor from 5 to 7 dpf (<xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5a, b</xref>). In contrast, <italic>ahctf1<sup>+/+</sup>;TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae exhibited a dose-dependent reduction in liver volume when exposed to Selinexor and this was reduced further by <italic>ahctf1</italic> heterozygosity (<xref ref-type="fig" rid="fig7s5">Figure 7—figure supplement 5c, d</xref>). Indeed, at a 1.00 µM concentration of Selinexor, liver volume in <italic>ahctf1<sup>+/−</sup></italic>;<italic>TO</italic>(<italic>kras<sup>G12V</sup></italic>)<italic><sup>T/+</sup></italic> larvae was indistinguishable from that of control <italic>2-CLiP</italic> larvae, indicating that liver overgrowth was completely blocked. These observations suggest that Selinexor could be an effective and selective suppressor of growth and proliferation in human HCC, and that its efficacy may be enhanced by combinatorial targeting with novel therapeutics designed to disrupt the function of the ELYS protein.</p></sec><sec id="s2-11"><title>Targeting NUPs is a promising therapeutic approach for HCC</title><p>To explore the clinical rationale for developing NUP inhibitors for the purpose of HCC treatment, we analysed gene expression data available for 366 patient samples in TCGA liver hepatocellular carcinoma (LIHC) dataset (<xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>) using the cBioPortal for Cancer Genomics (<xref ref-type="bibr" rid="bib7">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Gao et al., 2013</xref>). <italic>Z</italic>-score values were allocated to mRNA expression levels (RNAseq V2 RSEM) for each of the genes encoding the 10 components of the NUP107–160 complex relative to the mean expression value of that gene in diploid samples. Using this approach, we found a higher percentage of HCC samples overexpressing NUP mRNAs (<italic>z</italic>-score &gt;2) than those under-expressing NUP mRNAs (<italic>z</italic>-score &lt;2). For example, in the case of <italic>AHCTF1</italic>, 32.4% of patient samples had a <italic>z</italic>-score of &gt;2 relative to the mean expression of samples in the LIHC cohort that were diploid for <italic>AHCTF1</italic>. Conversely, only 0.82% of patient samples had a <italic>z</italic>-score of &lt;−2 for <italic>AHCTF1</italic> relative to its expression in samples that were diploid for this gene (<xref ref-type="fig" rid="fig8">Figure 8a</xref>).</p><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Targeting nuclear pore complexes (NPCs) is a promising therapeutic approach for hepatocellular carcinoma (HCC).</title><p>(<bold>a</bold>) Heatmap based on percentage of hepatocellular carcinoma (LIHC) samples in The Cancer Genome Atlas (TCGA) with mRNA expression levels of NUP107–160 components that are under-expressed (<italic>z</italic>-score &lt;−2: over 2 standard deviations below the mean expression of those genes in diploid samples) or overexpressed (<italic>z</italic>-score &gt;2: over 2 standard deviations above the mean expression of those genes in diploid samples) analysed through the cBioPortal for Cancer Genomics (<xref ref-type="bibr" rid="bib7">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Gao et al., 2013</xref>). See <xref ref-type="supplementary-material" rid="fig8sdata1">Figure 8—source data 1</xref>. (<bold>b</bold>) Probability of overall survival of HCC patients linked to samples with mRNA expression <italic>z</italic>-scores &gt;2 for one or more NUP107–160 complex components (red line; 63 cases); median probability of overall survival 21.70 months. Probability of overall survival of HCC patients linked to samples with mRNA expression <italic>z</italic>-scores &lt;−2 for one or more NUP107–160 complex components (blue line; 45 cases); median probability of overall survival 81.73 months. (<bold>c</bold>) Schematic depiction of two cellular processes disrupted by mild Elys depletion, leading to (<bold>d</bold>) accumulation of DNA damage and activation of Tp53 transcription programmes. (<bold>e</bold>) Induction of cell death and cell cycle arrest in hyperproliferative oncogene-expressing cancer cells.</p><p><supplementary-material id="fig8sdata1"><label>Figure 8—source data 1.</label><caption><title><xref ref-type="fig" rid="fig8">Figure 8a</xref>: mRNA expression <italic>z</italic>-scores (RNAseq V2 RSEM) for <italic>AHCTF1</italic> and the nine other genes encoding components of the NUP107–160 complex, relative to the mean expression of each gene of interest in patient samples that are diploid for that gene.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-73407-fig8-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>NUP107–160 complex gene expression in the The Cancer Genome Atlas (TCGA) liver hepatocellular carcinoma (LIHC) dataset is largely unaffected by unwanted variation.</title><p>The expression patterns of the genes encoding the 10 components of the NUP107–160 complex across sequencing plates in the TCGA LIHC RNA-Seq dataset. The <italic>X</italic> axes show the IDs for the 19 sequencing plates, and the <italic>Y</italic> axes represent <italic>z</italic>-scores of gene expression. The differences between average expression across individual sequencing plates were tested using analysis of variation (ANOVA) (<xref ref-type="bibr" rid="bib36">Molania et al., 2022</xref>).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-73407-fig8-figsupp1-v2.tif"/></fig></fig-group><p>To determine whether differences in NUP gene expression were associated with overall survival, we analysed the clinical data available for patients in the LIHC dataset. Here, log-transformed mRNA expression <italic>z</italic>-scores were calculated relative to the expression distribution of the ten 107–160 NUP genes across all 366 patient samples. This was followed by a logrank test to compare the survival distributions of patients linked to samples in the high expression group (<italic>z</italic>-score &gt;2) versus patients linked to samples in the low expression (<italic>z</italic>-score &lt;−2.0) group. We found that patients linked to samples with high mRNA expression <italic>z</italic>-scores (&gt;2.0) for one or more NUP107–160 components appeared to do significantly worse than patients with samples in the low expression group (<italic>z</italic>-score &lt;−2.0). Indeed, the median probability of overall survival for patients allocated to the high expression group was 21.70 months compared to 81.73 months (3.8-fold increase) for patients allocated to the low expression group (<xref ref-type="fig" rid="fig8">Figure 8b</xref>). We infer from these clinical data that patients with HCCs expressing high levels of mRNAs encoding ELYS and other components of the NUP107–160 complex may benefit most from strategies designed to target these NUP components therapeutically.</p><p>To examine the integrity of these interesting clinical data, we determined whether unwanted variation affected the expression levels of the NUP107–160 complex genes in samples of the LIHC dataset. If present, unwanted variation caused by factors such as differences in library size, tumour purity/heterogeneity and batch effects between participating laboratories, can significantly adversely affect downstream analyses including association between gene expression and survival outcomes (<xref ref-type="bibr" rid="bib36">Molania et al., 2022</xref>). Since the 366 samples of the LIHC dataset were profiled across 19 sequencing plates that could potentially cause batch effects, we addressed this issue by performing analysis of variation (ANOVA) tests (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). These tests revealed that the expression of our genes of interest in the LIHC dataset was largely unaffected by unwanted variation, increasing confidence that the inverse relationship we report here between upregulated NUP107–160 gene expression and poorer overall survival rate is likely to be reliable.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this paper we show that the presence of one mutant <italic>ahctf1</italic> allele markedly reduces hepatocyte growth and survival in a mutant <italic>kras-</italic>driven model of HCC. In our experiments <italic>ahctf1</italic> heterozygosity reduced the abundance of NPCs and introduced defects in mitotic spindle assembly and chromosome segregation only in hepatocytes expressing the <italic>kras<sup>G12V</sup></italic> oncogene (<xref ref-type="fig" rid="fig8">Figure 8c</xref>). These perturbations combined to amplify the mild oncogenic stress exhibited by cells expressing the <italic>kras<sup>G12V</sup></italic> oncogene, culminating in DNA damage, Tp53 activation (<xref ref-type="fig" rid="fig8">Figure 8d</xref>) and increased expression of Tp53 target genes that promote apoptosis and cell cycle arrest (<xref ref-type="fig" rid="fig8">Figure 8e</xref>). The exquisite vulnerability of hepatocytes co-expressing the <italic>kras<sup>G12V</sup></italic> oncogene and a single mutated <italic>ahctf1</italic> allele demonstrates a synthetic lethal interaction between a powerful oncogene and heterozygous expression of an essential cellular gene. Such a finding is of significant interest considering the remarkable success of PARP1 inhibitors in the clinic and presents a potential new drug target for tumours expressing mutant KRAS, which has hitherto proven difficult to target directly.</p><p>Our results compliment a growing body of evidence that carcinogenesis places persistently high demands on essential cellular genes, including those encoding NUPs (<xref ref-type="bibr" rid="bib50">Sakuma et al., 2021</xref>). Sakuma et al. used siRNAs targeting 28 individual NUP genes to reduce the abundance of NPCs in the human melanoma-derived cell line, A375, and showed that this caused cell death (<xref ref-type="bibr" rid="bib50">Sakuma et al., 2021</xref>). Meanwhile, normal human pulmonary fibroblasts and retinal pigmental epithelium cells (RPE1), underwent a reversible cell cycle arrest instead, consistent with reports that quiescent cells generally require only low levels of NUP expression due to exceptional stability of assembled NPCs (<xref ref-type="bibr" rid="bib11">D’Angelo et al., 2009</xref>; <xref ref-type="bibr" rid="bib53">Toyama et al., 2013</xref>).</p><p>Mutations in <italic>TP53</italic>, or amplification/overexpression of its negative regulators <italic>MDM2</italic>/<italic>MDM4</italic>, occur in 30% of HCC cases (<xref ref-type="bibr" rid="bib58">Zucman-Rossi et al., 2015</xref>). Therefore, it was pertinent to ask whether the potential therapeutic effect of inhibiting ELYS function in a clinical setting would be diminished in tumours not expressing WT TP53 protein. To address this question, we studied the impact of <italic>ahctf1</italic> heterozygosity in zebrafish that were homozygous for mutant <italic>tp53</italic>. We found that loss of Tp53 function permitted markedly higher rates of hepatocyte growth and liver enlargement in the larval, mutant <italic>kras-</italic>driven model of HCC, whether they were WT or heterozygous for <italic>ahctf1</italic>. However, total liver volume in <italic>ahctf1</italic> HETS was 35% less than in WT, meaning that the capacity of <italic>ahctf1</italic> heterozygosity to reduce liver volume was not entirely dependent on availability of WT Tp53. However, from a therapeutic perspective, we think that obtaining the full benefit of targeting ELYS protein in the clinic is likely to be affected by the mutational status of TP53.</p><p>Dysregulation of nucleocytoplasmic transport is a common feature in a broad spectrum of cancers, usually arising from altered expression of nuclear pore components and/or nuclear transport receptors (<xref ref-type="bibr" rid="bib25">Kau et al., 2004</xref>). For example, the nuclear transport receptor XPO1 is frequently overexpressed in cancers, leading to mis-localisation and inactivation of tumour suppressor proteins (<xref ref-type="bibr" rid="bib56">Zheng et al., 2014a</xref>; <xref ref-type="bibr" rid="bib21">Hill et al., 2014</xref>). We found that in our zebrafish HCC model, treatment with a clinically validated XPO1 inhibitor, Selinexor, produced a dose-dependent reduction in liver enlargement, which was strongly augmented by <italic>ahctf1</italic> heterozygosity. We also found that trans heterozygosity of <italic>ahctf1</italic> and <italic>ranbp2</italic> produced a synergistic reduction in liver volume in both <italic>kras<sup>G12V</sup></italic>-expressing larvae and adults. Normal livers not expressing the <italic>TO(kras<sup>G12V</sup></italic>) transgene were completely unaffected by Selinexor treatment or <italic>ahctf1;ranbp2</italic> trans heterozygosity, suggesting that new drugs targeting the ELYS protein and/or other NUPs could be combined effectively with drugs that target nucleocytoplasmic transport without forfeiting cancer selectivity.</p><p>To date, the molecular topology of the ELYS protein is poorly defined. Further high-resolution structural characterisation is required to advance our molecular understanding of the extent to which discrete domains within the ELYS protein contribute to its various interactions, and to reveal opportunities to inhibit such regions for the purpose of disabling ELYS function therapeutically. Crystal structures of ELYS have shown that the β-propeller and α-helical domains in the N-terminal half of the ELYS protein bind to NUP160, and cryo-electron microscopy revealed the association of the ELYS C-terminal region with nucleosomes (<xref ref-type="bibr" rid="bib26">Kobayashi et al., 2019</xref>; <xref ref-type="bibr" rid="bib4">Bilokapic and Schwartz, 2013</xref>). However, ELYS and other NUPs in the NUP107–160 complex generally lack features that would facilitate high affinity binding with small drug-like molecules (<xref ref-type="bibr" rid="bib50">Sakuma et al., 2021</xref>; <xref ref-type="bibr" rid="bib35">Mitsopoulos et al., 2021</xref>). Notwithstanding this, rapidly emerging technological advances in drug development may provide alternative strategies to target the ELYS protein. For example, carefully controlled proteasomal degradation of proteins that participate in the oncogenic process using proteolysis targeting chimeras (PROTACs) is a rapidly advancing field in cancer therapy (<xref ref-type="bibr" rid="bib39">Ocaña and Pandiella, 2020</xref>). In parallel, emerging small molecule RNA-targeting technology is on course to permit direct modulation of the abundance of specific RNA transcripts for a variety of clinical purposes (<xref ref-type="bibr" rid="bib37">Mukherjee et al., 2020</xref>). In summary, we believe the findings from our in vivo model of HCC provide a strong and feasible rationale for the development of novel therapeutics that target ELYS function as well as suggesting potential avenues for effective combinatorial treatments.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>ahctf1</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">ENSDARG00000077530</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>ranbp2</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">ENSDARG00000093125</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Gene (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>tp53</italic></td><td align="left" valign="bottom">Ensembl</td><td align="left" valign="bottom">ENSDARG00000035559</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>ahctf1<sup>ti262</sup></italic> (TU)</td><td align="left" valign="bottom">European Zebrafish <break/>Resource Centre (EZRC)</td><td align="left" valign="bottom">ZDB-ALT-980203-1165</td><td align="left" valign="bottom">Also known as <italic>flotte lotte</italic></td></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>ranbp2<sup>s452</sup></italic><break/>(TU)</td><td align="left" valign="bottom">Heath Lab (see this paper; <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>)</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>Tp53<sup>zdf1</sup></italic><break/>(AB)</td><td align="left" valign="bottom">European Zebrafish Resource Centre (EZRC)</td><td align="left" valign="bottom">ZDB-ALT-050428-215201</td><td align="left" valign="bottom">Also known as <italic>Tp53<sup>M214K</sup></italic></td></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>Tg(fabp10:dsRed, <break/>ela31:GFP)<sup>gz12</sup></italic></td><td align="left" valign="bottom">Zhiyuan Gong, National University of Singapore</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18796162/">18796162</ext-link></td><td align="left" valign="bottom">Also known as <italic>Lipan</italic> or 2CLiP</td></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>Tg(fabp10:rtTA2s-M2;<break/>TRE2:EGFP-kras<sup>G12V</sup>)<sup>gz32</sup></italic></td><td align="left" valign="bottom">Zhiyuan Gong, National University of Singapore</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/23812423/">23812423</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent <break/>Zebrafish (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>Tg(actb2:SEC-Hsa.ANXA5-mKate2,cryaa:mCherry)<sup>uq24rp</sup></italic></td><td align="left" valign="bottom">Thomas Hall, Institute of Molecular Bioscience, University of Queensland</td><td align="left" valign="bottom">PMID:<ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/31754462/">31754462</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">mAb414<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">AbCam</td><td align="left" valign="bottom">Cat# ab24609</td><td align="left" valign="bottom">IF (1:750)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-γ-H2AX <break/>(Mouse monoclonal)</td><td align="left" valign="bottom">AbCam</td><td align="left" valign="bottom">Cat# ab11174</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-α-Tubulin DM1A <break/>(Mouse monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 3873</td><td align="left" valign="bottom">IF (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-cleaved Caspase3<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 9664</td><td align="left" valign="bottom">IF (1:250)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Donkey anti-Rabbit IgG (H+L) <break/>Highly Cross-Adsorbed Secondary <break/>Antibody, Alexa Fluor 647 <break/>(Donkey polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#: A31573</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-Mouse IgG (H+L) <break/>Cross-Adsorbed Secondary <break/>Antibody, Alexa Fluor 647<break/>(Goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#: A21235</td><td align="left" valign="bottom">IF (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Tp53 (9.1)<break/>(Mouse monoclonal)</td><td align="left" valign="bottom">AbCam</td><td align="left" valign="bottom">Cat# ab77813</td><td align="left" valign="bottom">WB (1:500)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-GAPDH (14C10)<break/>(Rabbit polyclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">Cat#: 2118</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Mouse <break/>Immunoglobulins/HRP <break/>(affinity isolated) (Goat <break/>polyclonal)</td><td align="left" valign="bottom">Dako</td><td align="left" valign="bottom">Cat#: P0447</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat Anti-Rabbit <break/>Immunoglobulins/HRP <break/>(affinity isolated) (Goat <break/>polyclonal)</td><td align="left" valign="bottom">Dako</td><td align="left" valign="bottom">Cat#: P0448</td><td align="left" valign="bottom">WB (1:5000)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Active Ras Pull-Down <break/>and Detection kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat#: 16117</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Click-iT Edu AF647 <break/>kit imaging kit</td><td align="left" valign="bottom">Invitrogen</td><td align="left" valign="bottom">Cat#: C10340</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Selinexor (KPT-330)</td><td align="left" valign="bottom">Gift of Karyopharm Therapeutics</td><td align="left" valign="bottom"/><td align="left" valign="bottom">XPO1 inhibitor</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxycycline</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Sigma D9891</td><td align="left" valign="bottom">20 μg/mL</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Sequence-based reagents</title><sec id="s4-1-1"><title>Table 1. Genotyping primers</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Name</th><th align="left" valign="top">Forward (5′–3′)</th><th align="left" valign="top">Reverse (5′–3′)</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>ahctf1<sup>ti262</sup></italic></td><td align="left" valign="top">TGACATGCATGCCCTCTCTG</td><td align="left" valign="top">TAGCTGCTCCTCGCTTACGT</td></tr><tr><td align="left" valign="top"><italic>ranbp2<sup>s452</sup></italic></td><td align="left" valign="top">CGCCGATCAAGAGGACGAAA</td><td align="left" valign="top">TGTCCGCCGTAACACTACTC</td></tr><tr><td align="left" valign="top"><italic>tp53</italic> wildtype</td><td align="left" valign="top">AGCTGCATGGGGGGGAT</td><td align="left" valign="top">GATAGCCTAGTGCGAGCACACTCTT</td></tr><tr><td align="left" valign="top"><italic>tp53<sup>M214K</sup></italic></td><td align="left" valign="top">AGCTGCATGGGGGGGAA</td><td align="left" valign="top">GATAGCCTAGTGCGAGCACACTCTT</td></tr></tbody></table></table-wrap></sec><sec id="s4-1-2"><title>Table 2. RT-qPCR primers</title><table-wrap id="inlinetable2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Name</th><th align="left" valign="top">Forward (5′–3′)</th><th align="left" valign="top">Reverse (5′–3′)</th></tr></thead><tbody><tr><td align="left" valign="top"><italic>ahctf1<sup>ti262</sup></italic></td><td align="left" valign="top">GGTGAGTCAGTGTGGGGAAC</td><td align="left" valign="top">CCAGCAGGGCATGAAGTGAT</td></tr><tr><td align="left" valign="top"><italic>b2m</italic></td><td align="left" valign="top">GCGGTTGGGATTTACATGTTG</td><td align="left" valign="top">GCCTTCACCCCAGAGAAAGG</td></tr><tr><td align="left" valign="top"><italic>bad</italic></td><td align="left" valign="top">AGCAGCACCTCACTGTTCCT</td><td align="left" valign="top">CCAGTTTCCAGCAAGTCCTC</td></tr><tr><td align="left" valign="top"><italic>bax</italic></td><td align="left" valign="top">GGAGATGAGCTGGATGGAAA</td><td align="left" valign="top">GGGCCACTCTGATGAAGACA</td></tr><tr><td align="left" valign="top"><italic>bbc3</italic></td><td align="left" valign="top">GATGCCTTCAGCTTGGAC</td><td align="left" valign="top">GCCTGGACACTTCCTGTTCT</td></tr><tr><td align="left" valign="top"><italic>bcl2</italic></td><td align="left" valign="top">GGATCGAGGAAAATGGAGGT</td><td align="left" valign="top">AAAACGGGTGGAACACAGAG</td></tr><tr><td align="left" valign="top"><italic>bclxl</italic></td><td align="left" valign="top">CAACCATATTCAACCCTGGA</td><td align="left" valign="top">TTCTTGCGATTTCCTGCT</td></tr><tr><td align="left" valign="top"><italic>bid</italic></td><td align="left" valign="top">ACCAGCGACCTACAGAGACC</td><td align="left" valign="top">TCTGCATTGACTGAAAGACCA</td></tr><tr><td align="left" valign="top"><italic>bik</italic></td><td align="left" valign="top">TTGCTTCCACAGCTTCAAAA</td><td align="left" valign="top">ATGTAGTGCTGCGAGACCAG</td></tr><tr><td align="left" valign="top"><italic>bim</italic></td><td align="left" valign="top">GCACTTTGATTTCCCTCAGC</td><td align="left" valign="top">TGGAGAAAGTCCGGTTCATC</td></tr><tr><td align="left" valign="top"><italic>ccng1</italic></td><td align="left" valign="top">GTGCGGAGACGTTTTCCTT</td><td align="left" valign="top">AAGACAGATGCTTGGGCTGA</td></tr><tr><td align="left" valign="top"><italic>cdkn1a</italic></td><td align="left" valign="top">CAAGCCAAGAAGCGTCTAGTG</td><td align="left" valign="top">AACGGTGTCGTCTCTGGTTC</td></tr><tr><td align="left" valign="top"><italic>cdkn2a/b</italic></td><td align="left" valign="top">CGAGGATGAACTGACCACAGC</td><td align="left" valign="top">CAACAGCCAAAGGTGCGTTAC</td></tr><tr><td align="left" valign="top"><italic>hrpt1</italic></td><td align="left" valign="top">GAGGAGCGTTGGATACAGA</td><td align="left" valign="top">CTCGTTGTAGTCAAGTGCAT</td></tr><tr><td align="left" valign="top"><italic>mdm2</italic></td><td align="left" valign="top">TGACAAAGAAACTGGTAAGA</td><td align="left" valign="top">AAACATAACCTCCTTCATGGT</td></tr><tr><td align="left" valign="top"><italic>pmaip1</italic></td><td align="left" valign="top">ATGGCGAAGAAAGAGCAAAC</td><td align="left" valign="top">TCATCGCTTCCCCTCCATTTG</td></tr><tr><td align="left" valign="top"><italic>tbp</italic></td><td align="left" valign="top">CAGGCAACACACCACTTTAT</td><td align="left" valign="top">AAGTTTACGGTGGACACAAT</td></tr><tr><td align="left" valign="top"><italic>tp53</italic></td><td align="left" valign="top">TCCACTCTCCCACCAACATC</td><td align="left" valign="top">GGGAACCTGAGCCTAAATCC</td></tr><tr><td align="left" valign="top"><italic>tp63</italic></td><td align="left" valign="top">CGGCCTGTTTGGACTATTTC</td><td align="left" valign="top">ACTCCATGATGCCTTTCCAG</td></tr><tr><td align="left" valign="top"><italic>tp73</italic></td><td align="left" valign="top">GGCCAATCCTCATCATCATC</td><td align="left" valign="top">TCCCTGAATGGTCTTCGTC</td></tr><tr><td align="left" valign="top"><italic>∆113tp53</italic></td><td align="left" valign="top">ATATCCTGGCGAACATTTGG</td><td align="left" valign="top">ACGTCCACCACCATTTGAAC</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4-2"><title>Zebrafish maintenance and strains</title><p>Zebrafish were maintained at 28°C on a 12 hr light/12 hr dark cycle. The mutant lines <italic>ahctf1<sup>ti262</sup></italic> and <italic>tp53<sup>M214K/M214K</sup></italic> (also known as <italic>tp53<sup>e7/e7</sup></italic> and referred to herein as <italic>tp53<sup>m/m</sup></italic>) have been described previously (<xref ref-type="bibr" rid="bib9">Chen et al., 1996</xref>; <xref ref-type="bibr" rid="bib3">Berghmans et al., 2005</xref>). The Tg(<italic>fabp10:dsRed, ela3l:GFP</italic>)<sup>gz12</sup> line, herein referred to as <italic>2-CLiP</italic>, expresses dsRed in the liver and GFP in the exocrine pancreas but carries no oncogenic transgenes or mutations (<xref ref-type="bibr" rid="bib27">Korzh et al., 2008</xref>). The Tg(<italic>fabp10:rtTA2s-M2;TRE2:EGFP-kras<sup>G12V</sup></italic>)<sup>gz32</sup> line referred to as <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> and the cell death reporter line, Tg(<italic>actb2:SEC-Hsa.ANXA5-mKate2,cryaa:mCherry</italic>)<sup>uq24rp</sup> were described previously (<xref ref-type="bibr" rid="bib10">Chew et al., 2014</xref>; <xref ref-type="bibr" rid="bib19">Hall et al., 2019</xref>). The <italic>ranbp2<sup>s452</sup></italic> mutant line was generated in the Liver<sup>plus</sup> ENU mutagenesis screen (<xref ref-type="bibr" rid="bib38">Ober et al., 2006</xref>), and its genetic and morphological characterisation is presented for the first time in this paper.</p></sec><sec id="s4-3"><title>Inducing hepatocyte hyperplasia in larval zebrafish</title><p>To induce <italic>kras<sup>G12V</sup></italic> expression, <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> embryos were treated with 20 µg/mL dox (Sigma, #D9891) at 2 dpf in E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl<sub>2</sub>, 0.33 mM MgSO<sub>4</sub>) with 0.003% 1-phenyl-2-thiourea (PTU; Sigma, #P7629) to suppress pigmentation. E3 medium was changed at 5 dpf and fresh dox (final conc. 20 µg/mL) added. For the Selinexor experiments, the drug (final concentration 0.10–2.00 μM) (Karyopharm) or 0.001% DMSO (vehicle control) was added at 5 dpf. Morphological and molecular analyses were performed at 7 dpf. To quantitate liver volume, larvae were anaesthetised with benzocaine (200 mg/L) and mounted in 1% agarose. Image acquisition was performed using an Olympus FVMPE-RS multiphoton microscope with a ×25 objective and Olympus FV30-SW software. Excitation wavelengths for GFP and RFP were 840 and 1100 nm, respectively. For volumetric analysis of whole livers, z-stacks with step size 2 μm were imported into ImageJ or Imaris software.</p></sec><sec id="s4-4"><title>Inducing HCC in adult zebrafish</title><p>To induce <italic>kras<sup>G12V</sup></italic> expression, adult <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> zebrafish (&gt;3 months post-fertilisation) were treated for 7 days with 20 mg/L doxycycline (Sigma, #D9891) with water and dox changed daily. Zebrafish were euthanised with benzocaine (1000 mg/L) and tumour burden quantified by liver-to-body mass ratio measurements.</p></sec><sec id="s4-5"><title>Genotyping</title><p>Genomic DNA (gDNA) was extracted from whole zebrafish larvae by incubation at 95°C in 50 μL of 50 mM sodium hydroxide (NaOH) for 20 min, followed by neutralisation with 5 μL of 1 M Tris–HCl (pH 8.0). Primer sequences for genotyping are listed in Table 1.</p></sec><sec id="s4-6"><title>mRNA expression analysis</title><p>Total RNA was extracted from independent pools of micro-dissected zebrafish livers using the RNeasy Micro Kit (QIAGEN, #74004). RNA integrity was assessed by a High Sensitivity RNA ScreenTape assay (Agilent, #5067-5579) on a 2200 TapeStation. cDNA was generated from 1 to 10 µg RNA using the Superscript III First Strand Synthesis System (Invitrogen, #18080051) and oligo(dT) priming according to the manufacturer’s instructions. RT-qPCR was performed using a SensiMix SYBR kit (Bioline, #QT605-05) on an Applied Biosystems ViiATM7 Real-Time PCR machine. Expression data were normalised by reference to <italic>hrpt1</italic>, <italic>b2m</italic>, and <italic>tbp</italic>. LinRegPCR V11.0 was used for baseline correction, PCR efficiency calculation and transcript quantification analysis (<xref ref-type="bibr" rid="bib49">Ruijter et al., 2009</xref>). Relative expression levels were calculated by the 2<sup>−∆∆Ct</sup> method and all results were expressed as the mean ± standard error of the mean (SEM) of three independent pools of biological replicates. Primer sequences for RT-qPCR are listed in Table 2.</p></sec><sec id="s4-7"><title>Library preparation and RNA sequencing</title><p>RNA was isolated from individually micro-dissected livers and 100 ng per sample of RNA was used for RNA-sequencing library preparation using the TruSeq RNA Sample Prep Kit with Ribo-Zero depletion (Illumina). Indexed libraries were sequenced on a NextSeq 500 instrument (Illumina) to generate 80-bp paired end reads and yielding at least 20 million reads per sample. All samples were aligned to the GRCz11 build of the zebrafish genome using the align function from the Rsubread software package (v2.0.1) (<xref ref-type="bibr" rid="bib30">Liao et al., 2019</xref>). In all cases at least 75% of fragments (read pairs) were successfully mapped. All fragments overlapping genes were counted using Rsubread’s featureCounts function. Genes were identified using Ensembl annotation (v101). Differential expression analyses between the sample groups were then undertaken using the limma (v3.46.0) (<xref ref-type="bibr" rid="bib45">Ritchie et al., 2015</xref>) and edgeR (v3.32.1) (<xref ref-type="bibr" rid="bib46">Robinson et al., 2010</xref>) software packages. Expression-based filtering was performed using edgeR’s filterByExpr function with default parameters. A total of 21,655 genes remained. Sample composition was normalised using the TMM method (<xref ref-type="bibr" rid="bib47">Robinson and Oshlack, 2010</xref>). These data were transformed to log-counts per million (logCPM) with associated observation level precision weights using voom (<xref ref-type="bibr" rid="bib29">Law et al., 2014</xref>). Linear models were fit to the data and robust empirical Bayes moderated <italic>t</italic>-statistics were utilised to identify differentially expressed genes (<xref ref-type="bibr" rid="bib42">Phipson et al., 2016</xref>) through application of edgeR’s voomLmFit pipeline. The false discovery rate was controlled below 5% using the Benjamini and Hochberg method. The mean difference plot was generated using limma’s plotMD function and the heatmap using the pheatmap software package (v1.0.12). Gene set enrichment analysis was conducted with limma’s cameraPR function with default parameters, and the associated barcode plots drawn with limma’s barcodeplot function. Pathway analyses of the kyoto encyclopedia of genes and genomes (KEGG) database were accomplished using limma’s kegga function. The data have been deposited in the GEO under accession number GSE220282.</p></sec><sec id="s4-8"><title>Western blot analysis</title><p>Pooled micro-dissected zebrafish livers were lysed in RIPA buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.9, 150 mM NaCl, 1 mM MgCl<sub>2</sub>, 1% NP40, 10 mM NaF, 0.2 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM β-glycerol phosphate) supplemented with cOmplete Proteinase Inhibitor (Roche, #11836170001) and PhosTOP phosphatase inhibitors (Roche, #04906837001). Samples were incubated for 30 min on ice and the extracts cleared by centrifugation at 13,000 rpm for 20 min at 4°C. The protein concentration of samples was determined by BCA protein assay (Thermo Fisher Scientific, #23227). 25 μg of protein per lane were resolved on NuPAGE Novex Bis-Tris 4–12% polyacrylamide gels (Invitrogen, #NP0321BOX) and transferred onto nitrocellulose blotting membranes (Amersham Protran, #10600003). Membranes were blocked with 5% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 1 hr at room temperature (RT) and incubated with primary antibodies 1:500 Anti-p53 (9.1) mouse mAb (Abcam, #ab77813) overnight at 4°C and 1:1000 Anti-GAPDH (14C10) Rabbit mAb (Cell Signalling Technology, #2118) for 1 hr at RT. Secondary antibodies: Goat anti-mouse HRP (Dako, #P0447) and Goat anti-Rabbit HRP (Dako, #P0448) were used at 1:5000 and incubated with membranes for 1 hr at RT. Signals were developed using Amersham ECL Western Blotting Detection Kit (Cytiva, # RPN2108) and imaged on a Chemidoc Touch (Bio-Rad). Relative protein quantitation was calculated based on normalised integrated intensity.</p></sec><sec id="s4-9"><title>Active Ras pull-down and detection</title><p>Total lysate was isolated from 7 dpf zebrafish larvae and equal amounts of protein (50 μg) were used as input for the pull-down of activated GTP-Ras proteins using the Active Ras Pull-Down and Detection kit (Thermo Fisher, #16117) according to the manufacturers’ instructions.</p></sec><sec id="s4-10"><title>Cell death analysis</title><p>To assess apoptosis, 7 dpf <italic>TO(kras<sup>G12V</sup>);Annexin 5-mKate</italic> zebrafish larvae were fixed in 4% paraformaldehyde (PFA) overnight at 4°C and livers isolated by micro-dissection. Image acquisition was performed using a Zeiss LSM 880 microscope with a ×20 objective and ZEN software. Excitation wavelengths for mKate and GFP were 560 and 900 nm, respectively. Liver volume was quantified and 3D segmentation of Annexin 5-mKate signals were performed in ImageJ.</p></sec><sec id="s4-11"><title>Analysis of DNA replication in S-phase</title><p>EdU incorporation was used to assess the percentage of cells in S-phase of the cell cycle. Briefly, live zebrafish larvae (7 dpf) were incubated at 28°C in 2 mM EdU (Invitrogen, #C10340) in E3 medium for 2 hr followed by a further incubation in fresh E3 medium for 1 hr. Larvae were euthanised using benzocaine (1000 mg/L; Sigma, #PHR1158) prior to removal of the liver by micro-dissection. EdU labelling was carried out using the Click-iT Edu Alexa Fluor 647 (AF647) imaging kit (Invitrogen, #C10340), according to the manufacturer’s instructions. The livers were co-stained with Hoechst 33342 (Thermo Fisher, #62249). Image acquisition was performed using an Olympus FVMPE-RS multiphoton microscope with excitation wavelengths of 950 nm for Hoechst 33342 dye and 1160 nm for AF647 (Thermo Fisher, #A21235). The number of Hoechst 33342- and EdU-positive cells was quantified using Arivis Vision4D software.</p></sec><sec id="s4-12"><title>Nuclear pore analysis</title><p>Larvae fixed in 4% PFA overnight at 4°C were embedded in 4% low-melting temperature agarose and transverse sections collected at 200 µm intervals using a vibrating microtome (Leica VT 1000S). Sections were blocked with 1% BSA in PBS/0.3% Triton X-100 and incubated with a 1:750 dilution of mAb414 (Abcam, #ab24609) at 4°C overnight. Sections were then incubated with 1:500 anti-mouse AF647 and Hoechst 33342 at room temperature for 1 hr. Sections were mounted and imaged using a Zeiss LSM880 Fast Airyscan Confocal microscope with a ×63 objective. 3D segmentation of cells was performed in ImageJ using EGFP signal for <italic>TO(kras<sup>G12V</sup>)<sup>T/+</sup></italic> larvae or F-actin stained with 1:200 rhodamine phalloidin for <italic>TO(kras<sup>G12V</sup>)<sup>+/+</sup></italic> larvae. An outline was drawn around the nuclear periphery and segmented using the Hoechst signal. mAb414 fluorescence intensity was calculated for the nuclear periphery and for the cytoplasm. NPC density was calculated by finding maxima for mAb414 at the nuclear surface of 5 nuclei per liver.</p></sec><sec id="s4-13"><title>Cryosectioning and immunofluorescence microscopy analysis</title><p>Dissected livers were fixed in 4% PFA overnight at 4°C and washed with PBS/0.1% Tween 20 before incubation in 30% sucrose in PBS overnight at 4°C. Livers were aligned in a tissue mould, embedded in OCT and frozen on dry ice. The livers were sectioned at 10µm intervals using a Thermo Fisher Scientific Microm HM550 cryostat. Sections were washed with PBS before blocking with 10% FCS in PBS/0.3% Triton X-100. Incubation with primary antibodies was performed at 4°C overnight, while incubation with secondary antibodies was performed at room temperature for 1 hr. Antibodies used in this work were: 1:2000 a-Tubulin DM1A (CST, #3873), 1:1000 γ-H2AX (gift of James Amatruda), 1:250 cleaved caspase-3 (CST, #9664), 1:500 anti-rabbit AF647 (Thermo Fisher Scientific, #A31573) and 1:500 anti-mouse AF647 (Thermo Fisher, #A21235). Prolong Diamond Antifade reagent with DAPI (Thermo Fisher #P36962) was used for slide mounting. A Zeiss LSM880 Fast Airyscan Confocal microscope with a ×63 objective was used for image acquisition and ImageJ for image analysis.</p></sec><sec id="s4-14"><title>TCGA LIHC dataset analysis</title><p>Gene expression values for patient samples in the LIHC dataset in the TCGA, PanCancer Atlas were analysed using cBioPortal (<xref ref-type="bibr" rid="bib7">Cerami et al., 2012</xref>; <xref ref-type="bibr" rid="bib15">Gao et al., 2013</xref>). The NUP107–160 complex genes <italic>AHCTF1</italic>, <italic>NUP37</italic>, <italic>NUP43</italic>, <italic>NUP85</italic>, <italic>NUP98</italic>, <italic>NUP107</italic>, <italic>NUP133</italic>, <italic>NUP160</italic>, <italic>SEC12</italic>, and <italic>SEH1L</italic> were queried in samples with mRNA data (RNA Seq V2 RSEM). Patient samples were assigned to groups with high or low expression of one or more NUP107–160 complex genes based on <italic>z</italic>-scores &gt;2 and &lt;−2.0, respectively, relative to diploid samples. Patient samples that overlapped the selected groups were excluded from the overall survival analysis.</p></sec><sec id="s4-15"><title>Statistical analysis</title><p>Data are expressed as mean ± standard error of the mean (SEM), unless indicated otherwise, and the number of biological replicates indicating samples from individual animals/livers, or pools of individual animals/livers for each experiment are stated in the figure legends. p values were calculated using Student’s <italic>t</italic>-tests (two-tailed, followed by Welch’s correction) when comparing two groups, and by ANOVA followed by Tukey’s post hoc test when comparing multiple groups. Chi-square tests were used to analyse the distribution of mitotic cells and the number of mitotic cells exhibiting an aberrant phenotype. The effect of Selinexor treatment on liver volume was analysed by linear regression, regressing liver volume against Selinexor concentration. All analysis was performed using GraphPad Prism V7.03 (GraphPad software) and p values ≤0.05 were considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf3"><p>Reviewing editor, <italic>eLife</italic></p></fn><fn fn-type="COI-statement" id="conf4"><p>Senior editor, <italic>eLife</italic></p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Formal analysis, Supervision, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Investigation, Methodology</p></fn><fn fn-type="con" id="con13"><p>Methodology</p></fn><fn fn-type="con" id="con14"><p>Methodology</p></fn><fn fn-type="con" id="con15"><p>Methodology</p></fn><fn fn-type="con" id="con16"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All husbandry and experimental procedures performed on zebrafish followed standard operating procedures and were conducted with the approval of the Animal Ethics Committees of the Walter and Eliza Hall Institute and The University of Melbourne, Parkville, Victoria, Australia. WEHI-AEC approved project 2019.014, project title: Zebrafish disease models and mechanisms.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-73407-transrepform1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>A new RNA sequencing dataset has been deposited in GEO under accession ID GSE220282. Existing datasets analysed during the current study are available in the cBioPortal Cancer Genomics database (<ext-link ext-link-type="uri" xlink:href="http://www.cbioportal.org">http://www.cbioportal.org</ext-link>). All data generated/analysed during this study are included in the Figures and figure supplements and Source Data files are provided for Figures 1–8.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Garnham</surname><given-names>A</given-names></name><name><surname>Heath</surname><given-names>J</given-names></name><name><surname>Doggett</surname><given-names>K</given-names></name><name><surname>Morgan</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>Molecular characterisation of a mutant kras-driven zebrafish model of hepatocellular carcinoma</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE220282">GSE220282</pub-id></element-citation></p><p>The following previously published dataset was used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><collab>TCGA PanCancer Atlas</collab></person-group><year iso-8601-date="2018">2018</year><data-title>Liver Hepatocellular Carcinoma</data-title><source>cBioPortal Cancer Genomics database</source><pub-id pub-id-type="accession" xlink:href="https://www.cbioportal.org/study/summary?id=lihc_tcga_pan_can_atlas_2018">Genomics</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>The authors thank Tyson Blanch, Cameron Mackey, Elizabeth Grgacic, and Bryan Ko for excellent zebrafish husbandry and Ellen Tsui for histology. We are grateful to Assoc Prof Kimberley Evason for reviewing the zebrafish liver histology, Prof James Amatruda for the gift of rabbit polyclonal antibody to zebrafish γ-H2AX and Karyopharm Therapeutics for the gift of Selinexor. We thank Drs Andrew Cox, Leigh Coultas, Alexandra Garnham, Quentin Gouil, Assoc Prof Brendon Monahan, and Prof Gordon Smyth for bioinformatics support and insightful discussions.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MJ</given-names></name><name><surname>Rubio</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Active gtpase pulldown protocol</article-title><source>Methods in Molecular Biology</source><volume>2262</volume><fpage>117</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1190-6_7</pub-id><pub-id pub-id-type="pmid">33977474</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>M</given-names></name><name><surname>Hurt</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The nuclear pore complex: understanding its function through structural insight</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>18</volume><fpage>73</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1038/nrm.2016.147</pub-id><pub-id pub-id-type="pmid">27999437</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berghmans</surname><given-names>S</given-names></name><name><surname>Murphey</surname><given-names>RD</given-names></name><name><surname>Wienholds</surname><given-names>E</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Kutok</surname><given-names>JL</given-names></name><name><surname>Fletcher</surname><given-names>CDM</given-names></name><name><surname>Morris</surname><given-names>JP</given-names></name><name><surname>Liu</surname><given-names>TX</given-names></name><name><surname>Schulte-Merker</surname><given-names>S</given-names></name><name><surname>Kanki</surname><given-names>JP</given-names></name><name><surname>Plasterk</surname><given-names>R</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Look</surname><given-names>AT</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors</article-title><source>PNAS</source><volume>102</volume><fpage>407</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1073/pnas.0406252102</pub-id><pub-id pub-id-type="pmid">15630097</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bilokapic</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>TU</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Structural and functional studies of the 252 kda nucleoporin ELYS reveal distinct roles for its three tethered domains</article-title><source>Structure</source><volume>21</volume><fpage>572</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.str.2013.02.006</pub-id><pub-id pub-id-type="pmid">23499022</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boglev</surname><given-names>Y</given-names></name><name><surname>Badrock</surname><given-names>AP</given-names></name><name><surname>Trotter</surname><given-names>AJ</given-names></name><name><surname>Du</surname><given-names>Q</given-names></name><name><surname>Richardson</surname><given-names>EJ</given-names></name><name><surname>Parslow</surname><given-names>AC</given-names></name><name><surname>Markmiller</surname><given-names>SJ</given-names></name><name><surname>Hall</surname><given-names>NE</given-names></name><name><surname>de Jong-Curtain</surname><given-names>TA</given-names></name><name><surname>Ng</surname><given-names>AY</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Ober</surname><given-names>EA</given-names></name><name><surname>Field</surname><given-names>HA</given-names></name><name><surname>Shin</surname><given-names>D</given-names></name><name><surname>Shin</surname><given-names>CH</given-names></name><name><surname>Hannan</surname><given-names>KM</given-names></name><name><surname>Hannan</surname><given-names>RD</given-names></name><name><surname>Pearson</surname><given-names>RB</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Ess</surname><given-names>KC</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Autophagy induction is a tor- and tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis</article-title><source>PLOS Genetics</source><volume>9</volume><elocation-id>e1003279</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1003279</pub-id><pub-id pub-id-type="pmid">23408911</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calvisi</surname><given-names>DF</given-names></name><name><surname>Ladu</surname><given-names>S</given-names></name><name><surname>Gorden</surname><given-names>A</given-names></name><name><surname>Farina</surname><given-names>M</given-names></name><name><surname>Conner</surname><given-names>EA</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Factor</surname><given-names>VM</given-names></name><name><surname>Thorgeirsson</surname><given-names>SS</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Ubiquitous activation of ras and JAK/STAT pathways in human HCC</article-title><source>Gastroenterology</source><volume>130</volume><fpage>1117</fpage><lpage>1128</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2006.01.006</pub-id><pub-id pub-id-type="pmid">16618406</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Gross</surname><given-names>BE</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Byrne</surname><given-names>CJ</given-names></name><name><surname>Heuer</surname><given-names>ML</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Antipin</surname><given-names>Y</given-names></name><name><surname>Reva</surname><given-names>B</given-names></name><name><surname>Goldberg</surname><given-names>AP</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The cbio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discovery</source><volume>2</volume><fpage>401</fpage><lpage>404</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatel</surname><given-names>G</given-names></name><name><surname>Fahrenkrog</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Nucleoporins: leaving the nuclear pore complex for a successful mitosis</article-title><source>Cellular Signalling</source><volume>23</volume><fpage>1555</fpage><lpage>1562</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2011.05.023</pub-id><pub-id pub-id-type="pmid">21683138</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JN</given-names></name><name><surname>Haffter</surname><given-names>P</given-names></name><name><surname>Odenthal</surname><given-names>J</given-names></name><name><surname>Vogelsang</surname><given-names>E</given-names></name><name><surname>Brand</surname><given-names>M</given-names></name><name><surname>van Eeden</surname><given-names>FJ</given-names></name><name><surname>Furutani-Seiki</surname><given-names>M</given-names></name><name><surname>Granato</surname><given-names>M</given-names></name><name><surname>Hammerschmidt</surname><given-names>M</given-names></name><name><surname>Heisenberg</surname><given-names>CP</given-names></name><name><surname>Jiang</surname><given-names>YJ</given-names></name><name><surname>Kane</surname><given-names>DA</given-names></name><name><surname>Kelsh</surname><given-names>RN</given-names></name><name><surname>Mullins</surname><given-names>MC</given-names></name><name><surname>Nüsslein-Volhard</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Mutations affecting the cardiovascular system and other internal organs in zebrafish</article-title><source>Development</source><volume>123</volume><fpage>293</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1242/dev.123.1.293</pub-id><pub-id pub-id-type="pmid">9007249</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>TW</given-names></name><name><surname>Liu</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Spitsbergen</surname><given-names>JM</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name><name><surname>Low</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Crosstalk of ras and rho: activation of rhoa abates KRAS-induced liver tumorigenesis in transgenic zebrafish models</article-title><source>Oncogene</source><volume>33</volume><fpage>2717</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.240</pub-id><pub-id pub-id-type="pmid">23812423</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Angelo</surname><given-names>MA</given-names></name><name><surname>Raices</surname><given-names>M</given-names></name><name><surname>Panowski</surname><given-names>SH</given-names></name><name><surname>Hetzer</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Age-dependent deterioration of nuclear pore complexes causes a loss of nuclear integrity in postmitotic cells</article-title><source>Cell</source><volume>136</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.11.037</pub-id><pub-id pub-id-type="pmid">19167330</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davuluri</surname><given-names>G</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Yusuff</surname><given-names>S</given-names></name><name><surname>Lorent</surname><given-names>K</given-names></name><name><surname>Muthumani</surname><given-names>M</given-names></name><name><surname>Dolan</surname><given-names>AC</given-names></name><name><surname>Pack</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Mutation of the zebrafish nucleoporin ELYS sensitizes tissue progenitors to replication stress</article-title><source>PLOS Genetics</source><volume>4</volume><elocation-id>e1000240</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1000240</pub-id><pub-id pub-id-type="pmid">18974873</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Jong-Curtain</surname><given-names>TA</given-names></name><name><surname>Parslow</surname><given-names>AC</given-names></name><name><surname>Trotter</surname><given-names>AJ</given-names></name><name><surname>Hall</surname><given-names>NE</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Tabone</surname><given-names>T</given-names></name><name><surname>Christie</surname><given-names>EL</given-names></name><name><surname>Crowhurst</surname><given-names>MO</given-names></name><name><surname>Layton</surname><given-names>JE</given-names></name><name><surname>Shepherd</surname><given-names>IT</given-names></name><name><surname>Nixon</surname><given-names>SJ</given-names></name><name><surname>Parton</surname><given-names>RG</given-names></name><name><surname>Zon</surname><given-names>LI</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Abnormal nuclear pore formation triggers apoptosis in the intestinal epithelium of elys-deficient zebrafish</article-title><source>Gastroenterology</source><volume>136</volume><fpage>902</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2008.11.012</pub-id><pub-id pub-id-type="pmid">19073184</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franz</surname><given-names>C</given-names></name><name><surname>Walczak</surname><given-names>R</given-names></name><name><surname>Yavuz</surname><given-names>S</given-names></name><name><surname>Santarella</surname><given-names>R</given-names></name><name><surname>Gentzel</surname><given-names>M</given-names></name><name><surname>Askjaer</surname><given-names>P</given-names></name><name><surname>Galy</surname><given-names>V</given-names></name><name><surname>Hetzer</surname><given-names>M</given-names></name><name><surname>Mattaj</surname><given-names>IW</given-names></name><name><surname>Antonin</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>MEL-28/ELYS is required for the recruitment of nucleoporins to chromatin and postmitotic nuclear pore complex assembly</article-title><source>EMBO Reports</source><volume>8</volume><fpage>165</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1038/sj.embor.7400889</pub-id><pub-id pub-id-type="pmid">17235358</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Aksoy</surname><given-names>BA</given-names></name><name><surname>Dogrusoz</surname><given-names>U</given-names></name><name><surname>Dresdner</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>B</given-names></name><name><surname>Sumer</surname><given-names>SO</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Jacobsen</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>Larsson</surname><given-names>E</given-names></name><name><surname>Cerami</surname><given-names>E</given-names></name><name><surname>Sander</surname><given-names>C</given-names></name><name><surname>Schultz</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative analysis of complex cancer genomics and clinical profiles using the cbioportal</article-title><source>Science Signaling</source><volume>6</volume><elocation-id>pl1</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.2004088</pub-id><pub-id pub-id-type="pmid">23550210</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Synthetic lethality in drug development: the dawn is coming</article-title><source>Future Medicinal Chemistry</source><volume>10</volume><fpage>2129</fpage><lpage>2132</lpage><pub-id pub-id-type="doi">10.4155/fmc-2018-0227</pub-id><pub-id pub-id-type="pmid">30043635</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gillespie</surname><given-names>PJ</given-names></name><name><surname>Khoudoli</surname><given-names>GA</given-names></name><name><surname>Stewart</surname><given-names>G</given-names></name><name><surname>Swedlow</surname><given-names>JR</given-names></name><name><surname>Blow</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>ELYS/MEL-28 chromatin association coordinates nuclear pore complex assembly and replication licensing</article-title><source>Current Biology</source><volume>17</volume><fpage>1657</fpage><lpage>1662</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2007.08.041</pub-id><pub-id pub-id-type="pmid">17825564</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Güttinger</surname><given-names>S</given-names></name><name><surname>Laurell</surname><given-names>E</given-names></name><name><surname>Kutay</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Orchestrating nuclear envelope disassembly and reassembly during mitosis</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>10</volume><fpage>178</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1038/nrm2641</pub-id><pub-id pub-id-type="pmid">19234477</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>TE</given-names></name><name><surname>Wood</surname><given-names>AJ</given-names></name><name><surname>Ehrlich</surname><given-names>O</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Sonntag</surname><given-names>CS</given-names></name><name><surname>Cole</surname><given-names>NJ</given-names></name><name><surname>Huttner</surname><given-names>IG</given-names></name><name><surname>Sztal</surname><given-names>TE</given-names></name><name><surname>Currie</surname><given-names>PD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Cellular rescue in a zebrafish model of congenital muscular dystrophy type 1A</article-title><source>NPJ Regenerative Medicine</source><volume>4</volume><elocation-id>21</elocation-id><pub-id pub-id-type="doi">10.1038/s41536-019-0084-5</pub-id><pub-id pub-id-type="pmid">31754462</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashizume</surname><given-names>C</given-names></name><name><surname>Kobayashi</surname><given-names>A</given-names></name><name><surname>Wong</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Down-modulation of nucleoporin ranbp2/nup358 impaired chromosomal alignment and induced mitotic catastrophe</article-title><source>Cell Death &amp; Disease</source><volume>4</volume><elocation-id>e854</elocation-id><pub-id pub-id-type="doi">10.1038/cddis.2013.370</pub-id><pub-id pub-id-type="pmid">24113188</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>R</given-names></name><name><surname>Cautain</surname><given-names>B</given-names></name><name><surname>de Pedro</surname><given-names>N</given-names></name><name><surname>Link</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Targeting nucleocytoplasmic transport in cancer therapy</article-title><source>Oncotarget</source><volume>5</volume><fpage>11</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.1457</pub-id><pub-id pub-id-type="pmid">24429466</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>C</given-names></name><name><surname>Mathavan</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Transcriptomic analyses of oncogenic hepatocytes reveal common and different molecular pathways of hepatocarcinogenesis in different developmental stages and genders in krasg12v transgenic zebrafish</article-title><source>Biochemical and Biophysical Research Communications</source><volume>510</volume><fpage>558</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2019.02.008</pub-id><pub-id pub-id-type="pmid">30739784</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jans</surname><given-names>DA</given-names></name><name><surname>Martin</surname><given-names>AJ</given-names></name><name><surname>Wagstaff</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Inhibitors of nuclear transport</article-title><source>Current Opinion in Cell Biology</source><volume>58</volume><fpage>50</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2019.01.001</pub-id><pub-id pub-id-type="pmid">30826604</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>ST</given-names></name><name><surname>Jablonski</surname><given-names>SA</given-names></name><name><surname>Yen</surname><given-names>TJ</given-names></name><name><surname>Dasso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The rangap1-ranbp2 complex is essential for microtubule-kinetochore interactions in vivo</article-title><source>Current Biology</source><volume>14</volume><fpage>611</fpage><lpage>617</lpage><pub-id pub-id-type="doi">10.1016/j.cub.2004.03.031</pub-id><pub-id pub-id-type="pmid">15062103</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kau</surname><given-names>TR</given-names></name><name><surname>Way</surname><given-names>JC</given-names></name><name><surname>Silver</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Nuclear transport and cancer: from mechanism to intervention</article-title><source>Nature Reviews. Cancer</source><volume>4</volume><fpage>106</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1038/nrc1274</pub-id><pub-id pub-id-type="pmid">14732865</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>W</given-names></name><name><surname>Takizawa</surname><given-names>Y</given-names></name><name><surname>Aihara</surname><given-names>M</given-names></name><name><surname>Negishi</surname><given-names>L</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Kurumizaka</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural and biochemical analyses of the nuclear pore complex component ELYS identify residues responsible for nucleosome binding</article-title><source>Communications Biology</source><volume>2</volume><elocation-id>163</elocation-id><pub-id pub-id-type="doi">10.1038/s42003-019-0385-7</pub-id><pub-id pub-id-type="pmid">31069272</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korzh</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Garcia-Lecea</surname><given-names>M</given-names></name><name><surname>Winata</surname><given-names>CL</given-names></name><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Wohland</surname><given-names>T</given-names></name><name><surname>Korzh</surname><given-names>V</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Requirement of vasculogenesis and blood circulation in late stages of liver growth in zebrafish</article-title><source>BMC Developmental Biology</source><volume>8</volume><elocation-id>84</elocation-id><pub-id pub-id-type="doi">10.1186/1471-213X-8-84</pub-id><pub-id pub-id-type="pmid">18796162</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhn</surname><given-names>TM</given-names></name><name><surname>Pascual-Garcia</surname><given-names>P</given-names></name><name><surname>Gozalo</surname><given-names>A</given-names></name><name><surname>Little</surname><given-names>SC</given-names></name><name><surname>Capelson</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Chromatin targeting of nuclear pore proteins induces chromatin decondensation</article-title><source>The Journal of Cell Biology</source><volume>218</volume><fpage>2945</fpage><lpage>2961</lpage><pub-id pub-id-type="doi">10.1083/jcb.201807139</pub-id><pub-id pub-id-type="pmid">31366666</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Voom: precision weights unlock linear model analysis tools for RNA-seq read counts</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>R29</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2014-15-2-r29</pub-id><pub-id pub-id-type="pmid">24485249</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>Y</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads</article-title><source>Nucleic Acids Research</source><volume>47</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkz114</pub-id><pub-id pub-id-type="pmid">30783653</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lord</surname><given-names>CJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Parp inhibitors: synthetic lethality in the clinic</article-title><source>Science</source><volume>355</volume><fpage>1152</fpage><lpage>1158</lpage><pub-id pub-id-type="doi">10.1126/science.aam7344</pub-id><pub-id pub-id-type="pmid">28302823</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Emanuele</surname><given-names>MJ</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Creighton</surname><given-names>CJ</given-names></name><name><surname>Schlabach</surname><given-names>MR</given-names></name><name><surname>Westbrook</surname><given-names>TF</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>A genome-wide rnai screen identifies multiple synthetic lethal interactions with the ras oncogene</article-title><source>Cell</source><volume>137</volume><fpage>835</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.05.006</pub-id><pub-id pub-id-type="pmid">19490893</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Markmiller</surname><given-names>S</given-names></name><name><surname>Cloonan</surname><given-names>N</given-names></name><name><surname>Lardelli</surname><given-names>RM</given-names></name><name><surname>Doggett</surname><given-names>K</given-names></name><name><surname>Keightley</surname><given-names>MC</given-names></name><name><surname>Boglev</surname><given-names>Y</given-names></name><name><surname>Trotter</surname><given-names>AJ</given-names></name><name><surname>Ng</surname><given-names>AY</given-names></name><name><surname>Wilkins</surname><given-names>SJ</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Ober</surname><given-names>EA</given-names></name><name><surname>Field</surname><given-names>HA</given-names></name><name><surname>Grimmond</surname><given-names>SM</given-names></name><name><surname>Lieschke</surname><given-names>GJ</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Heath</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Minor class splicing shapes the zebrafish transcriptome during development</article-title><source>PNAS</source><volume>111</volume><fpage>3062</fpage><lpage>3067</lpage><pub-id pub-id-type="doi">10.1073/pnas.1305536111</pub-id><pub-id pub-id-type="pmid">24516132</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>RK</given-names></name><name><surname>Chakraborty</surname><given-names>P</given-names></name><name><surname>Arnaoutov</surname><given-names>A</given-names></name><name><surname>Fontoura</surname><given-names>BMA</given-names></name><name><surname>Dasso</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The nup107-160 complex and gamma-turc regulate microtubule polymerization at kinetochores</article-title><source>Nature Cell Biology</source><volume>12</volume><fpage>164</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1038/ncb2016</pub-id><pub-id pub-id-type="pmid">20081840</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitsopoulos</surname><given-names>C</given-names></name><name><surname>Di Micco</surname><given-names>P</given-names></name><name><surname>Fernandez</surname><given-names>EV</given-names></name><name><surname>Dolciami</surname><given-names>D</given-names></name><name><surname>Holt</surname><given-names>E</given-names></name><name><surname>Mica</surname><given-names>IL</given-names></name><name><surname>Coker</surname><given-names>EA</given-names></name><name><surname>Tym</surname><given-names>JE</given-names></name><name><surname>Campbell</surname><given-names>J</given-names></name><name><surname>Che</surname><given-names>KH</given-names></name><name><surname>Ozer</surname><given-names>B</given-names></name><name><surname>Kannas</surname><given-names>C</given-names></name><name><surname>Antolin</surname><given-names>AA</given-names></name><name><surname>Workman</surname><given-names>P</given-names></name><name><surname>Al-Lazikani</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>CanSAR: update to the cancer translational research and drug discovery knowledgebase</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>D1074</fpage><lpage>D1082</lpage><pub-id pub-id-type="doi">10.1093/nar/gkaa1059</pub-id><pub-id pub-id-type="pmid">33219674</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molania</surname><given-names>R</given-names></name><name><surname>Foroutan</surname><given-names>M</given-names></name><name><surname>Gagnon-Bartsch</surname><given-names>JA</given-names></name><name><surname>Gandolfo</surname><given-names>LC</given-names></name><name><surname>Jain</surname><given-names>A</given-names></name><name><surname>Sinha</surname><given-names>A</given-names></name><name><surname>Olshansky</surname><given-names>G</given-names></name><name><surname>Dobrovic</surname><given-names>A</given-names></name><name><surname>Papenfuss</surname><given-names>AT</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Removing unwanted variation from large-scale RNA sequencing data with prps</article-title><source>Nature Biotechnology</source><volume>41</volume><fpage>82</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1038/s41587-022-01440-w</pub-id><pub-id pub-id-type="pmid">36109686</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>H</given-names></name><name><surname>Blain</surname><given-names>JC</given-names></name><name><surname>Vandivier</surname><given-names>LE</given-names></name><name><surname>Chin</surname><given-names>DN</given-names></name><name><surname>Friedman</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Maillet</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>C</given-names></name><name><surname>Kaplan</surname><given-names>JB</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Chenoweth</surname><given-names>DM</given-names></name><name><surname>Christensen</surname><given-names>AB</given-names></name><name><surname>Petersen</surname><given-names>LK</given-names></name><name><surname>Hansen</surname><given-names>NJV</given-names></name><name><surname>Barrera</surname><given-names>L</given-names></name><name><surname>Kubica</surname><given-names>N</given-names></name><name><surname>Kumaravel</surname><given-names>G</given-names></name><name><surname>Petter</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>PEARL-seq: a photoaffinity platform for the analysis of small molecule-RNA interactions</article-title><source>ACS Chemical Biology</source><volume>15</volume><fpage>2374</fpage><lpage>2381</lpage><pub-id pub-id-type="doi">10.1021/acschembio.0c00357</pub-id><pub-id pub-id-type="pmid">32804474</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname><given-names>EA</given-names></name><name><surname>Verkade</surname><given-names>H</given-names></name><name><surname>Field</surname><given-names>HA</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mesodermal wnt2b signalling positively regulates liver specification</article-title><source>Nature</source><volume>442</volume><fpage>688</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nature04888</pub-id><pub-id pub-id-type="pmid">16799568</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ocaña</surname><given-names>A</given-names></name><name><surname>Pandiella</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proteolysis targeting chimeras (protacs) in cancer therapy</article-title><source>Journal of Experimental &amp; Clinical Cancer Research</source><volume>39</volume><elocation-id>189</elocation-id><pub-id pub-id-type="doi">10.1186/s13046-020-01672-1</pub-id><pub-id pub-id-type="pmid">32933565</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okita</surname><given-names>K</given-names></name><name><surname>Kiyonari</surname><given-names>H</given-names></name><name><surname>Nobuhisa</surname><given-names>I</given-names></name><name><surname>Kimura</surname><given-names>N</given-names></name><name><surname>Aizawa</surname><given-names>S</given-names></name><name><surname>Taga</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Targeted disruption of the mouse ELYS gene results in embryonic death at peri-implantation development</article-title><source>Genes to Cells</source><volume>9</volume><fpage>1083</fpage><lpage>1091</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2443.2004.00791.x</pub-id><pub-id pub-id-type="pmid">15507119</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petrovic</surname><given-names>S</given-names></name><name><surname>Mobbs</surname><given-names>GW</given-names></name><name><surname>Bley</surname><given-names>CJ</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name><name><surname>Patke</surname><given-names>A</given-names></name><name><surname>Hoelz</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Structure and function of the nuclear pore complex</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>14</volume><elocation-id>a041264</elocation-id><pub-id pub-id-type="doi">10.1101/cshperspect.a041264</pub-id><pub-id pub-id-type="pmid">36096637</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Majewski</surname><given-names>IJ</given-names></name><name><surname>Alexander</surname><given-names>WS</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Robust hyperparameter estimation protects against hypervariable genes and improves power to detect differential expression</article-title><source>The Annals of Applied Statistics</source><volume>10</volume><fpage>946</fpage><lpage>963</lpage><pub-id pub-id-type="doi">10.1214/16-AOAS920</pub-id><pub-id pub-id-type="pmid">28367255</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasala</surname><given-names>BA</given-names></name><name><surname>Orjalo</surname><given-names>AV</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Briggs</surname><given-names>S</given-names></name><name><surname>Forbes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>ELYS is a dual nucleoporin/kinetochore protein required for nuclear pore assembly and proper cell division</article-title><source>PNAS</source><volume>103</volume><fpage>17801</fpage><lpage>17806</lpage><pub-id pub-id-type="doi">10.1073/pnas.0608484103</pub-id><pub-id pub-id-type="pmid">17098863</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rasala</surname><given-names>BA</given-names></name><name><surname>Ramos</surname><given-names>C</given-names></name><name><surname>Harel</surname><given-names>A</given-names></name><name><surname>Forbes</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Capture of AT-rich chromatin by ELYS recruits POM121 and NDC1 to initiate nuclear pore assembly</article-title><source>Molecular Biology of the Cell</source><volume>19</volume><fpage>3982</fpage><lpage>3996</lpage><pub-id pub-id-type="doi">10.1091/mbc.e08-01-0012</pub-id><pub-id pub-id-type="pmid">18596237</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Research</source><volume>43</volume><elocation-id>e47</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id><pub-id pub-id-type="pmid">25605792</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>EdgeR: a bioconductor package for differential expression analysis of digital gene expression data</article-title><source>Bioinformatics</source><volume>26</volume><fpage>139</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp616</pub-id><pub-id pub-id-type="pmid">19910308</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>MD</given-names></name><name><surname>Oshlack</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>A scaling normalization method for differential expression analysis of RNA-seq data</article-title><source>Genome Biology</source><volume>11</volume><elocation-id>R25</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2010-11-3-r25</pub-id><pub-id pub-id-type="pmid">20196867</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rogakou</surname><given-names>EP</given-names></name><name><surname>Pilch</surname><given-names>DR</given-names></name><name><surname>Orr</surname><given-names>AH</given-names></name><name><surname>Ivanova</surname><given-names>VS</given-names></name><name><surname>Bonner</surname><given-names>WM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Dna double-stranded breaks induce histone H2AX phosphorylation on serine 139</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>5858</fpage><lpage>5868</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.10.5858</pub-id><pub-id pub-id-type="pmid">9488723</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruijter</surname><given-names>JM</given-names></name><name><surname>Ramakers</surname><given-names>C</given-names></name><name><surname>Hoogaars</surname><given-names>WMH</given-names></name><name><surname>Karlen</surname><given-names>Y</given-names></name><name><surname>Bakker</surname><given-names>O</given-names></name><name><surname>van den Hoff</surname><given-names>MJB</given-names></name><name><surname>Moorman</surname><given-names>AFM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data</article-title><source>Nucleic Acids Research</source><volume>37</volume><elocation-id>e45</elocation-id><pub-id pub-id-type="doi">10.1093/nar/gkp045</pub-id><pub-id pub-id-type="pmid">19237396</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuma</surname><given-names>S</given-names></name><name><surname>Raices</surname><given-names>M</given-names></name><name><surname>Borlido</surname><given-names>J</given-names></name><name><surname>Guglielmi</surname><given-names>V</given-names></name><name><surname>Zhu</surname><given-names>EYS</given-names></name><name><surname>D’Angelo</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Inhibition of nuclear pore complex formation selectively induces cancer cell death</article-title><source>Cancer Discovery</source><volume>11</volume><fpage>176</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-20-0581</pub-id><pub-id pub-id-type="pmid">32988961</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salina</surname><given-names>D</given-names></name><name><surname>Enarson</surname><given-names>P</given-names></name><name><surname>Rattner</surname><given-names>JB</given-names></name><name><surname>Burke</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Nup358 integrates nuclear envelope breakdown with kinetochore assembly</article-title><source>The Journal of Cell Biology</source><volume>162</volume><fpage>991</fpage><lpage>1001</lpage><pub-id pub-id-type="doi">10.1083/jcb.200304080</pub-id><pub-id pub-id-type="pmid">12963708</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solimini</surname><given-names>NL</given-names></name><name><surname>Luo</surname><given-names>J</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Non-oncogene addiction and the stress phenotype of cancer cells</article-title><source>Cell</source><volume>130</volume><fpage>986</fpage><lpage>988</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.09.007</pub-id><pub-id pub-id-type="pmid">17889643</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toyama</surname><given-names>BH</given-names></name><name><surname>Savas</surname><given-names>JN</given-names></name><name><surname>Park</surname><given-names>SK</given-names></name><name><surname>Harris</surname><given-names>MS</given-names></name><name><surname>Ingolia</surname><given-names>NT</given-names></name><name><surname>Yates</surname><given-names>JR</given-names></name><name><surname>Hetzer</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification of long-lived proteins reveals exceptional stability of essential cellular structures</article-title><source>Cell</source><volume>154</volume><fpage>971</fpage><lpage>982</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2013.07.037</pub-id><pub-id pub-id-type="pmid">23993091</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Hughes</surname><given-names>NW</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Kendirli</surname><given-names>A</given-names></name><name><surname>Klein</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>WW</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic ras</article-title><source>Cell</source><volume>168</volume><fpage>890</fpage><lpage>903</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.013</pub-id><pub-id pub-id-type="pmid">28162770</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Koch</surname><given-names>B</given-names></name><name><surname>Walczak</surname><given-names>R</given-names></name><name><surname>Ciray-Duygu</surname><given-names>F</given-names></name><name><surname>González-Sánchez</surname><given-names>JC</given-names></name><name><surname>Devos</surname><given-names>DP</given-names></name><name><surname>Mattaj</surname><given-names>IW</given-names></name><name><surname>Gruss</surname><given-names>OJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The nucleoporin MEL-28 promotes rangtp-dependent γ-tubulin recruitment and microtubule nucleation in mitotic spindle formation</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>3270</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms4270</pub-id><pub-id pub-id-type="pmid">24509916</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Gery</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Shacham</surname><given-names>S</given-names></name><name><surname>Kauffman</surname><given-names>M</given-names></name><name><surname>Koeffler</surname><given-names>HP</given-names></name></person-group><year iso-8601-date="2014">2014a</year><article-title>KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma</article-title><source>Cancer Chemotherapy and Pharmacology</source><volume>74</volume><fpage>487</fpage><lpage>495</lpage><pub-id pub-id-type="doi">10.1007/s00280-014-2495-8</pub-id><pub-id pub-id-type="pmid">25030088</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Emelyanov</surname><given-names>A</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2014">2014b</year><article-title>Xmrk, KRAS and myc transgenic zebrafish liver cancer models share molecular signatures with subsets of human hepatocellular carcinoma</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e91179</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0091179</pub-id><pub-id pub-id-type="pmid">24633177</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zucman-Rossi</surname><given-names>J</given-names></name><name><surname>Villanueva</surname><given-names>A</given-names></name><name><surname>Nault</surname><given-names>JC</given-names></name><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Genetic landscape and biomarkers of hepatocellular carcinoma</article-title><source>Gastroenterology</source><volume>149</volume><fpage>1226</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2015.05.061</pub-id><pub-id pub-id-type="pmid">26099527</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73407.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.08.25.457580" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.25.457580"/></front-stub><body><p>We believe that the study demonstrates the importance of nuclear pore complex components for Kras/p53 driven liver tumors. The findings made here in zebrafish may stimulate additional preclinical and mechanistic studies to test the role of nuclear pore components in cancer.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73407.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Zhu</surname><given-names>Hao</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00t9vx427</institution-id><institution>University of Texas Southwestern Medical Center</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.08.25.457580">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.08.25.457580v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Elys deficiency constrains Kras-driven tumour burden by amplifying oncogenic stress&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, including Hao Zhu as the Reviewing Editor and Reviewer #1, and the evaluation has been overseen by Richard White as the Senior Editor.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1. Please determine if tp63 and tp73 are compensating for tp53 loss. One possibility is to knockdown these genes (perhaps using CRISPR/Cas9) in the presence and absence of tp53. The finding that tp63/tp73 knockdown suppresses apoptosis in tp53 mutants but not in tp53 wild-type zebrafish would support your stated hypothesis.</p><p>2. Please determine if ahctf1 heterozygosity indeed decreases liver tumor burden in the TO(kras) model. This experiment in adult zebrafish should be fairly straightforward. The finding that ahctf1+/- have decreased liver tumor burden (quantified by liver-to-body-mass ratio and histologic analysis) would bolster the significance of this work greatly.</p><p>3. When referring to larval liver size, the language of the paper should be changed to &quot;liver overgrowth&quot; rather than &quot;tumor burden&quot;.</p><p>4. Statistical analysis (error bars) are missing on Figure 6c and d.</p><p>5. In the krasG12V model, it would be helpful to distinguish the contribution of increased cell death vs decreased cell proliferation to the change in liver size seen with heterozygous ahctf1. Is this predominantly due to decreased proliferation?</p><p>6. Please determine if the heterozygous ahctf1 state blunts the overall level of Ras activity in krasG12V animals.</p><p>7. It would be helpful to see detailed transcriptional profiling of hepatocytes in the krasG12V model with the heterozygous ahctf1 mutation, and to assess the effects of Selinexor. GSEA type analysis offers a way to start untangling the effects of these pathways. Moreover this analysis could provide insight on the relevance of this model to human HCC. Please let un know if it is feasible to generate this data within a reasonable time frame.</p><p>8. Functions of Achtf1 in regard to chromatin regulation could be compromised in this model. Scholz et al. (Nat Gen 2019) report that Ahctf1 is involved in increasing Myc expression via gene gating mechanism. What are effects on Myc in this system?</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>I see that this dependency in mammalian cells is described in the discussion, but I think that adding some mammalian cancer cell line data showing the effect of one allele ahctf1 deletion would be highly informative. Also, if the authors could cite a paper showing that het mice are viable and normal, that would be useful.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. To determine if tp63 and tp73 are compensating for tp53 loss, it would be interesting to knock down these genes (perhaps using CRISPR/Cas9) in the presence and absence of tp53. The finding that tp63/tp73 knockdown suppresses apoptosis in tp53 mutants but not in tp53 wild-type zebrafish would support your hypothesis.</p><p>2. It would be REALLY interesting to see if ahctf1 heterozygosity indeed decreases liver tumor burden in the TO(kras) model. This experiment in adult zebrafish should be fairly straightforward. The finding that ahctf1+/- have decreased liver tumor burden (quantified by liver-to-body-mass ratio and histologic analysis) would bolster the significance of this work greatly.</p><p>3. When referring to larval liver size, the language of the paper should be changed to &quot;liver overgrowth&quot; rather than &quot;tumor burden&quot;.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.73407.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1. Please determine if tp63 and tp73 are compensating for tp53 loss. One possibility is to knockdown these genes (perhaps using CRISPR/Cas9) in the presence and absence of tp53. The finding that tp63/tp73 knockdown suppresses apoptosis in tp53 mutants but not in tp53 wild-type zebrafish would support your stated hypothesis.</p></disp-quote><p>Our claim that &quot;the beneficial effect of <italic>ahctf1</italic> heterozygosity to reduce tumour burden persists in the absence of functional Tp53 due to compensatory increases in the levels of <italic>tp63</italic> and <italic>tp73</italic>” was an overstatement and has now been deleted. While our data demonstrated higher levels of <italic>tp63</italic> and <italic>tp73</italic> mRNA expression in response to <italic>ahctf1</italic> heterozygosity and Tp53 loss, we presented no data to indicate that this was due to activation of a compensation mechanism. Indeed, the mechanism(s) underlying genetic compensation are not well understood and therefore difficult to test (El-Brolosy MA and Stainier DYR 2017. PLoS Genet 13, e1006780).</p><p>While Reviewer 2 suggests that Crispr/Cas9 knock-out experiments may help us to resolve this question, we think that the results of these experiments would be of limited relevance in a clinical context, since the human <italic>TP63</italic> and <italic>TP73</italic> genes are rarely mutated in cancer. Also, we would need to generate viable triple mutant zebrafish to undertake these experiments, and these will be extremely rare/non-viable, as is the case in mice (Van Nostrand JL <italic>et al.</italic> Cell Death Diff doi:10.1038/cdd.2016.128). Instead, we have replaced the contentious text in a new paragraph (see below), which can be found in the revised manuscript on page 14, lines 291-298.</p><p>“We also noted that mRNAs encoding the Tp53 family members, Tp63 and Tp73 were upregulated by 3.0-fold and 2.3-fold, respectively, in heterozygous <italic>ahctf1</italic> livers, compared to WT <italic>ahctf1</italic> livers, in the presence of WT Tp53 (blue bars; Figure 6e). Interestingly, in the absence of WT Tp53 (purple bars, Figure 6e), <italic>ahctf1</italic> heterozygosity further enhanced the expression of <italic>tp63</italic> and <italic>tp73</italic>, albeit mildly. Since <italic>tp63</italic> and <italic>tp73</italic> are not direct Tp53 target genes, this raises the possibility that <italic>tp63</italic> and/or <italic>tp73</italic> expression mediate a Tp53-independent role in the inhibition of hepatocyte growth in response to <italic>ahctf1</italic> heterozygosity. Tp63 and Tp73 have several direct target genes in common with Tp53, including the pro-apoptotic genes, <italic>bbc3</italic>, <italic>pmaip1</italic>, <italic>bim</italic> and <italic>bax</italic>, and the cell cycle arrest gene, <italic>cdkna1</italic>.”</p><disp-quote content-type="editor-comment"><p>2. Please determine if ahctf1 heterozygosity indeed decreases liver tumor burden in the TO(kras) model. This experiment in adult zebrafish should be fairly straightforward. The finding that ahctf1+/- have decreased liver tumor burden (quantified by liver-to-body-mass ratio and histologic analysis) would bolster the significance of this work greatly.</p></disp-quote><p>We thank Reviewer 2 for suggesting these experiments, and we agree that the new data we obtained from adults has greatly improved the significance of our study. In these experiments, adult zebrafish were treated daily with doxycycline for 7 d to induce <italic>kras<sup>G12V</sup></italic> expression, resulting in a 9-fold increase in the liver-to-body mass ratio in males (new Figure 1e), with similar results in females (Figure 1e). When we introduced <italic>ahctf1</italic> heterozygosity into this setting we observed a 30% reduction in liver-to-body mass ratio in both male and female adults (Figure 1e). These new results with adult zebrafish essentially recapitulate the findings we made with larvae and highlight the concordance between the developmental and adult models. We also carried out RNA sequencing and gene set enrichment analysis to compare differential gene expression between WT and dox-treated TO(<italic>kras<sup>G12V</sup>)<sup>T/+</sup></italic> larval livers (Figure 1—figure supplement 1). The significant correlation between the differential gene expression signature of KrasG12V expressing hepatocytes, compared to wildtype hepatocytes, and the differential gene signature of 369 patient samples in the Liver hepatocellular (LIHC) dataset of The Cancer Genome Atlas (TCGA), compared to healthy livers, provide additional confidence that our larval model of HCC is relevant to human HCC.</p><disp-quote content-type="editor-comment"><p>3. When referring to larval liver size, the language of the paper should be changed to &quot;liver overgrowth&quot; rather than &quot;tumor burden&quot;.</p></disp-quote><p>In all cases, including the title of the revised manuscript, where we used the term “tumour burden”, we have replaced the term with liver enlargement or liver overgrowth.</p><disp-quote content-type="editor-comment"><p>4. Statistical analysis (error bars) are missing on Figure 6c and d.</p></disp-quote><p>We have completed the statistical analysis as requested on what is now Figure 3 panels c, d (previously Figure 6c and d).</p><disp-quote content-type="editor-comment"><p>5. In the krasG12V model, it would be helpful to distinguish the contribution of increased cell death vs decreased cell proliferation to the change in liver size seen with heterozygous ahctf1. Is this predominantly due to decreased proliferation?</p></disp-quote><p>We think this question is difficult to address, because the relative contributions of the two processes may vary with time. Our data show definitively that by 7 dpf, the impact of <italic>ahctf1</italic> heterozygous mutation has disrupted multiple cellular processes, leading to a 40% increase in the number of hepatocytes expressing Annexin 5 (dying cells), and a 40% decrease in the number of hepatocytes incorporating EdU over a 2 h incubation (fewer cells in S-phase). Both responses are likely to contribute to the reduction in liver volume observed in response to <italic>ahctf1</italic> heterozygosity. It is worth stating that in our experiments, we captured snapshots of apoptosis and DNA replication in the livers of larvae at 7 days post-fertilisation after 5d of dox treatment/KrasG12V expression. To answer the Reviewer’s question properly, we would need to monitor the behaviour of individual cells over time. If such experiments were technically possible, we think that some cells that undergo growth arrest in response to dox treatment might ultimately succumb to apoptosis (unless dox treatment is withdrawn) while other cells might enter into a state of prolonged senescence. However, given the technical challenges, we did not attempt to test this in the current manuscript.</p><disp-quote content-type="editor-comment"><p>6. Please determine if the heterozygous ahctf1 state blunts the overall level of Ras activity in krasG12V animals.</p></disp-quote><p>We have addressed this interesting question thoroughly in new Figure 1g, h. To do this, we used a commercial RAS-RBD pulldown kit followed by western blot analysis to determine the levels of activated GTP-bound Kras protein. Our results demonstrate that the levels of GTP-bound Kras protein, expressed as a proportion of total Kras protein, do not change in response to <italic>ahctf1</italic> heterozygosity. We conclude from these data that the potentially therapeutic value of reduced <italic>ahctf1</italic> expression in a cancer setting is not caused by inhibiting Kras activity.</p><disp-quote content-type="editor-comment"><p>7. It would be helpful to see detailed transcriptional profiling of hepatocytes in the krasG12V model with the heterozygous ahctf1 mutation, and to assess the effects of Selinexor. GSEA type analysis offers a way to start untangling the effects of these pathways. Moreover this analysis could provide insight on the relevance of this model to human HCC. Please let un know if it is feasible to generate this data within a reasonable time frame.</p></disp-quote><p>Please also see our response to comment #2. We used RNAseq to address the relevance of our larval model to human HCC. Specifically, we performed differential gene expression analysis to identify up- and downregulated genes in cohorts of <italic>ahctf1</italic><sup>+/+</sup> (WT) larvae versus dox-treated <italic>ahctf1</italic><sup>+/+</sup>(WT);<italic>kras<sup>G12V</sup></italic> larvae. We used gene set enrichment analysis to compare these differentially regulated transcripts with the gene expression signature of 369 patient samples in the Liver hepatocellular carcinoma (LIHC) dataset versus healthy liver samples in the TCGA. These analyses revealed a significant association between the patterns of gene expression in our larval model of zebrafish HCC and those of human HCC (Figure 1—figure supplement 1c, d).</p><p>The genetic experiments we report in Figures 4, 5, 6 show that WT Tp53 is required for the reductions in liver enlargement (Figure 4), apoptosis (Figure 5) and DNA replication (Figure 6) that occurs in response to <italic>ahctf1</italic> heterozygosity in dox-treated <italic>kras<sup>G12V</sup></italic> larvae. We also used RT-qPCR to show that a Tp53-mediated transcriptional program was activated in these <italic>ahctf1</italic> heterozygous livers (Figure 5). Similarly, in <bold>adult</bold> livers, <italic>ahctf1</italic> heterozygosity triggered the upregulation of Tp53 target genes, including pro-apoptotic genes (<italic>pmaip1</italic>, <italic>bbc3, bim</italic> and <italic>bax</italic>) and cell cycle arrest genes (<italic>cdkn1a</italic> and <italic>ccng1</italic>) (new Figure 6—figure supplement 1). These results show that to obtain the full potential of <italic>ahctf1</italic> heterozygosity in reducing growth and survival of <italic>Kras<sup>G12V</sup></italic>-expressing hyperplastic hepatocytes requires activation of WT Tp53. This is an important conclusion from our paper that is likely to be relevant in a clinical setting, for instance in patient selection, if ELYS inhibitors are developed for the treatment of HCC in which the KRAS/MAPK pathway is activated.</p><p>Also, one reviewer mentions performing genome-wide transcriptional profiling of hepatocytes in the krasG12V model in response to <italic>ahctf1</italic> heterozygosity and the presence and absence of Selinexor treatment. While these are potentially interesting experiments, they are substantial in nature and not crucial for the main messages of our paper. Therefore, we respectively contend that they are beyond the scope of the current manuscript.</p><disp-quote content-type="editor-comment"><p>8. Functions of Achtf1 in regard to chromatin regulation could be compromised in this model. Scholz et al. (Nat Gen 2019) report that Ahctf1 is involved in increasing Myc expression via gene gating mechanism. What are effects on Myc in this system?</p></disp-quote><p>The Scholz, 2019 and Gondor, 2022 papers from the same group, are very interesting in that they demonstrate a novel role for the ELYS protein in addition to the ones we pursued in our paper. The authors showed that in HCT116 cells, a human colorectal cancer cell line in which proliferation is driven by aberrant WNT/CTNNB1 signalling, the longevity of nascent MYC mRNA was increased by accelerating its movement from the nucleus to the cytoplasm, thereby preventing its degradation by nuclear surveillance mechanisms. The authors showed that siRNA knockdown of AHCTF1 in HCT-116 cells reduced the rate of nuclear export of MYC transcripts without changing the transcriptional rate of the MYC gene. They proposed a mechanism that depended on the formation of a complex chromatin architecture comprising transcriptionally active MYC and CCAT1 alleles plus proteins including β-Catenin, CTCF and ELYS. Together these interacting components guided nascent MYC mRNA molecules to nuclear pores, enhanced their export to the cytoplasm to be translated, resulting in activation of a MYC transcriptional program that induced expression of pro-proliferation genes. In theory, this role of ELYS in protecting MYC from nuclear degradation might extrapolate to other cancer settings where MYC expression is elevated. While interplay between MYC and mutant KRAS to enhance cancer growth has been previously reported, to date, most emphasis on this interaction has focused on the role of mutant KRAS in increasing the stability of the MYC protein, for example via RAS effector protein kinases (ERK1/2 and ERK5) that stabilise MYC by phosphorylation at S62 (Farrell and Sears, 2014: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1101/cshperspect.a014365">https://doi.org/10.1101/cshperspect.a014365</ext-link>) (Vaseva and Blake 2018: DOI:<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ccell.2018.10.001)">https://doi.org/10.1016/j.ccell.2018.10.001)</ext-link>. While we appreciate the novelty of the recent papers, the current findings are limited to β-Catenin activated HCT-116 cells and may not be relevant to our zebrafish model of mutant Kras-driven HCC. Accordingly, we have not allocated a high priority to following this up in our current manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>I see that this dependency in mammalian cells is described in the discussion, but I think that adding some mammalian cancer cell line data showing the effect of one allele ahctf1 deletion would be highly informative.</p></disp-quote><p>Yes, we cited the Sakuma <italic>et al.</italic> paper in the Discussion (page 18, second paragraph) as an example of a cell line-based study demonstrating NUP dependence in cancer cells versus normal cells. In a separate study, a genome-wide CRISPR/Cas9 targeting/gene essentiality screen (Meyers et al., 2017) showed that <italic>AHCTF1</italic> is essential for the viability of all 342 cancer cell lines examined (curated in the GenomeCRISPR database <ext-link ext-link-type="uri" xlink:href="http://genomecrispr.dkfz.de/#!/">http://genomecrispr.dkfz.de/#!/</ext-link>) (Rauscher et al., 2017). While neither of these approaches address the specific question posed by this reviewer, they are consistent with the notion of NUP inhibitors offering a viable therapeutic window for cancer treatment. Against this background, we are hesitant to embark on the vagaries of picking one or more human cancer cell lines in which to delete one allele of <italic>AHCTF1</italic> as this could turn out to be a time-consuming and frustrating exercise. We prefer to stand by our in vivo approach, which we believe offered a cleaner, well-controlled system for our study.</p><disp-quote content-type="editor-comment"><p>Also, if the authors could cite a paper showing that het mice are viable and normal, that would be useful.</p></disp-quote><p>We have cited the paper on page 6, line 115 (Okita <italic>et al.</italic> ref 8), which shows that <italic>Ahctf1</italic> het mice are viable and normal.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>2. It would be REALLY interesting to see if ahctf1 heterozygosity indeed decreases liver tumor burden in the TO(kras) model. This experiment in adult zebrafish should be fairly straightforward. The finding that ahctf1+/- have decreased liver tumor burden (quantified by liver-to-body-mass ratio and histologic analysis) would bolster the significance of this work greatly.</p></disp-quote><p>We agree with these comments and accordingly, we performed several new experiments in adult fish. We have addressed this comprehensively under item #2</p><disp-quote content-type="editor-comment"><p>3. When referring to larval liver size, the language of the paper should be changed to &quot;liver overgrowth&quot; rather than &quot;tumor burden&quot;.</p></disp-quote><p>Notwithstanding our demonstration that the gene expression profile exhibited by our larval model of HCC is significantly associated with that of human HCC, we have used the terms liver enlargement and liver overgrowth instead of tumour burden throughout the manuscript, including the title (addressed under item #3).</p></body></sub-article></article>